

Structure-based design of antiviral drug candidates targeting HIV-1 protease

Science

368, 1331-1335

DOI: [10.1126/science.abb4489](https://doi.org/10.1126/science.abb4489)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Evaluation of NGS-based approaches for SARS-CoV-2 whole genome characterisation. <i>Virus Evolution</i> , 2020, 6, veaa075.	2.2	124
2	Quantitative Structure–Activity Relationship Machine Learning Models and their Applications for Identifying Viral 3CLpro- and RdRp-Targeting Compounds as Potential Therapeutics for COVID-19 and Related Viral Infections. <i>ACS Omega</i> , 2020, 5, 27344-27358.	1.6	31
3	Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 1719-1735.	2.0	26
4	Treatment for COVID-19: An overview. <i>European Journal of Pharmacology</i> , 2020, 889, 173644.	1.7	226
5	Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches. <i>Biochemical Pharmacology</i> , 2020, 182, 114225.	2.0	83
6	Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic. <i>Bioorganic Chemistry</i> , 2020, 104, 104315.	2.0	30
7	Potential use of polyphenols in the battle against COVID-19. <i>Current Opinion in Food Science</i> , 2020, 32, 149-155.	4.1	105
8	Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. <i>Frontiers in Microbiology</i> , 2020, 11, 2016.	1.5	11
9	Antiviral Drug Discovery To Address the COVID-19 Pandemic. <i>MBio</i> , 2020, 11, .	1.8	7
10	2020 update on human coronaviruses: One health, one world. <i>Medicine in Novel Technology and Devices</i> , 2020, 8, 100043.	0.9	21
11	Many small steps towards a COVID-19 drug. <i>Nature Communications</i> , 2020, 11, 5048.	5.8	18
12	Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2053-2066.	2.0	14
13	Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. <i>Nature</i> , 2020, 587, 657-662.	13.7	818
14	Biochemical screening for SARS-CoV-2 main protease inhibitors. <i>PLoS ONE</i> , 2020, 15, e0240079.	1.1	84
15	A systematic review of SARS-CoV-2 vaccine candidates. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 237.	7.1	427
16	Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1265-1277.	2.5	194
17	Unveiling the molecular mechanism of SARS-CoV-2 main protease inhibition from 137 crystal structures using algebraic topology and deep learning. <i>Chemical Science</i> , 2020, 11, 12036-12046.	3.7	62
18	Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12725-12747.	2.9	371

#	ARTICLE	IF	CITATIONS
19	Unusual zwitterionic catalytic site of SARS-CoV-2 main protease revealed by neutron crystallography. <i>Journal of Biological Chemistry</i> , 2020, 295, 17365-17373.	1.6	97
20	Alkaloids from <i>Cryptolepis sanguinolenta</i> as Potential Inhibitors of SARS-CoV-2 Viral Proteins: An <i>In Silico</i> Study. <i>BioMed Research International</i> , 2020, 2020, 1-14.	0.9	54
21	Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. <i>Antiviral Research</i> , 2020, 182, 104924.	1.9	33
22	Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface. <i>Computational Biology and Chemistry</i> , 2020, 89, 107372.	1.1	30
23	Structural insight into the recognition of S-adenosyl-L-homocysteine and sinefungin in SARS-CoV-2 Nsp16/Nsp10 RNA cap 2'-O-Methyltransferase. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 2757-2765.	1.9	25
24	Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 1363-1386.	2.0	58
25	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. <i>Nature Reviews Cardiology</i> , 2020, 17, 543-558.	6.1	999
26	In crystallo-screening for discovery of human norovirus 3C-like protease inhibitors. <i>Journal of Structural Biology: X</i> , 2020, 4, 100031.	0.7	2
27	Minireview of progress in the structural study of SARS-CoV-2 proteins. <i>Current Research in Microbial Sciences</i> , 2020, 1, 53-61.	1.4	43
28	Current and Perspective Diagnostic Techniques for COVID-19. <i>ACS Infectious Diseases</i> , 2020, 6, 1998-2016.	1.8	116
29	The increasing impact of Chinese innovative drug research on the global stage with a focus on drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1115-1120.	2.5	2
30	Current and Future Direct-Acting Antivirals Against COVID-19. <i>Frontiers in Microbiology</i> , 2020, 11, 587944.	1.5	16
31	Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m ^{pro}): a molecular docking, molecular dynamics and structure-activity relationship studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 3110-3128.	2.0	41
32	Overcoming nonstructural protein 15-nidoviral uridylylate-specific endoribonuclease (nsp15/NendoU) activity of SARS-CoV-2. <i>Future Drug Discovery</i> , 2020, 2, .	0.8	9
33	Exploring the Mechanism of Covalent Inhibition: Simulating the Binding Free Energy of Î±-Ketoamide Inhibitors of the Main Protease of SARS-CoV-2. <i>Biochemistry</i> , 2020, 59, 4601-4608.	1.2	45
34	Amino acid interacting network in the receptor-binding domain of SARS-CoV-2 spike protein. <i>RSC Advances</i> , 2020, 10, 39831-39841.	1.7	18
35	Cordycepin: a bioactive metabolite of <i>Cordyceps militaris</i> and polyadenylation inhibitor with therapeutic potential against COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, , 1-8.	2.0	30
36	SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 587269.	1.8	552

#	ARTICLE	IF	CITATIONS
37	Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. <i>Nature Communications</i> , 2020, 11, 5877.	5.8	141
38	Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease. <i>Virology Journal</i> , 2020, 17, 190.	1.4	73
39	Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 3777-3788.	2.0	20
40	Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 605236.	1.6	159
41	Docking Characterization and in vitro Inhibitory Activity of Flavan-3-ols and Dimeric Proanthocyanidins Against the Main Protease Activity of SARS-Cov-2. <i>Frontiers in Plant Science</i> , 2020, 11, 601316.	1.7	74
42	Advances toward COVID-19 Therapies Special Issue Call for Papers. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15073-15074.	2.9	1
43	Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 Mpro Protease. <i>Molecules</i> , 2020, 25, 5172.	1.7	42
44	Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2716-2746.	2.9	149
45	Assessing potential inhibitors of SARS-CoV-2 main protease from available drugs using free energy perturbation simulations. <i>RSC Advances</i> , 2020, 10, 40284-40290.	1.7	21
46	Interactive Molecular Dynamics in Virtual Reality Is an Effective Tool for Flexible Substrate and Inhibitor Docking to the SARS-CoV-2 Main Protease. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 5803-5814.	2.5	30
47	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. <i>Methods in Pharmacology and Toxicology</i> , 2020, , 329-431.	0.1	4
48	Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5346.	1.8	48
49	Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase. <i>Protein and Cell</i> , 2020, 11, 699-702.	4.8	18
50	The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020. <i>European Journal of Medicinal Chemistry</i> , 2020, 206, 112711.	2.6	119
51	Dynamical properties of enzyme-substrate complexes disclose substrate specificity of the SARS-CoV-2 main protease as characterized by the electron density descriptors. <i>Physical Chemistry Chemical Physics</i> , 2020, 22, 19069-19079.	1.3	29
52	Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. <i>Pharmaceuticals</i> , 2020, 13, 155.	1.7	88
53	Targeting SARS-CoV-2 RBD Interface: a Supervised Computational Data-Driven Approach to Identify Potential Modulators. <i>ChemMedChem</i> , 2020, 15, 1921-1931.	1.6	7
54	Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review. <i>Frontiers in Microbiology</i> , 2020, 11, 1723.	1.5	69

#	ARTICLE	IF	CITATIONS
55	While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?. <i>Frontiers in Physiology</i> , 2020, 11, 820.	1.3	13
56	Potential treatment methods targeting 2019-nCoV infection. <i>European Journal of Medicinal Chemistry</i> , 2020, 205, 112687.	2.6	32
57	Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1167-1177.	2.8	314
58	Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6689-6704.	2.0	11
59	Probing 3CL ^{pro} protease: Rationally designed chemical moieties for COVID-19. <i>Drug Development Research</i> , 2020, 81, 911-918.	1.4	10
60	Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds. <i>European Journal of Medicinal Chemistry</i> , 2020, 206, 112702.	2.6	45
61	Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 813-834.	2.5	25
62	Roles of flavonoids against coronavirus infection. <i>Chemico-Biological Interactions</i> , 2020, 328, 109211.	1.7	252
63	Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy. <i>Virus Research</i> , 2020, 288, 198102.	1.1	79
64	Hordatines as a Potential Inhibitor of COVID-19 Main Protease and RNA Polymerase: An In-Silico Approach. <i>Natural Products and Bioprospecting</i> , 2020, 10, 453-462.	2.0	11
65	Malleability of the SARS-CoV-2 3CL ^{pro} Active-Site Cavity Facilitates Binding of Clinical Antivirals. <i>Structure</i> , 2020, 28, 1313-1320.e3.	1.6	108
66	Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2526-2533.	1.3	176
67	Secondary metabolites from spice and herbs as potential multitarget inhibitors of SARS-CoV-2 proteins. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2264-2283.	2.0	68
68	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. <i>Journal of Proteome Research</i> , 2020, 19, 4291-4315.	1.8	68
69	Computational studies reveal mechanism by which quinone derivatives can inhibit SARS-CoV-2. Study of embelin and two therapeutic compounds of interest, methyl prednisolone and dexamethasone. <i>Journal of Infection and Public Health</i> , 2020, 13, 1868-1877.	1.9	34
70	Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation. <i>Scientific Reports</i> , 2020, 10, 16986.	1.6	54
71	Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease. <i>Physical Chemistry Chemical Physics</i> , 2020, 22, 25335-25343.	1.3	34
72	Optimization Rules for SARS-CoV-2 M ^{pro} Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site. <i>Viruses</i> , 2020, 12, 942.	1.5	34

#	ARTICLE	IF	CITATIONS
73	Managing the COVID-19 Pandemic: Research Strategies Based on the Evolutionary and Molecular Characteristics of Coronaviruses. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1767-1776.	0.3	3
74	What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks. <i>Dalton Transactions</i> , 2020, 49, 16004-16033.	1.6	58
75	Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL ^{pro} of novel coronavirus SARS-CoV-2 identified using docking and molecular dynamics. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 348-360.	2.0	20
76	Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1008-1016.	2.5	162
77	Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. <i>Nature Communications</i> , 2020, 11, 4417.	5.8	394
78	Several coumarin derivatives and their Pd(<i>ii</i>) complexes as potential inhibitors of the main protease of SARS-CoV-2, an <i>in silico</i> approach. <i>RSC Advances</i> , 2020, 10, 35099-35108.	1.7	37
79	Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis. <i>Medical Hypotheses</i> , 2020, 144, 110254.	0.8	33
80	Design and Synthesis of Antiviral Drug Candidates Targeting SARS-CoV-2 Main Protease. <i>Synfacts</i> , 2020, 16, 1105.	0.0	0
81	Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. <i>Nature Communications</i> , 2020, 11, 4282.	5.8	334
82	Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms. <i>Scientific Reports</i> , 2020, 10, 14214.	1.6	211
83	Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL ^{pro} Reporter Assay. <i>Journal of Virology</i> , 2020, 94, .	1.5	85
84	Promising inhibitors targeting M ^{pro} : an ideal strategy for anti-SARS-CoV-2 drug discovery. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 173.	7.1	11
85	Rapid prediction of possible inhibitors for SARS-CoV-2 main protease using docking and FPL simulations. <i>RSC Advances</i> , 2020, 10, 31991-31996.	1.7	30
86	Impact of Early Pandemic Stage Mutations on Molecular Dynamics of SARS-CoV-2 M ^{pro} . <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 5080-5102.	2.5	62
87	Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. <i>Journal of Proteome Research</i> , 2020, 19, 4670-4677.	1.8	55
88	On the intrinsic reactivity of highly potent trypanocidal cruzain inhibitors. <i>RSC Medicinal Chemistry</i> , 2020, 11, 1275-1284.	1.7	7
89	Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an <i>in silico</i> repurposing study. <i>Future Medicinal Chemistry</i> , 2020, 12, 1815-1828.	1.1	66
90	Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. <i>Microorganisms</i> , 2020, 8, 1250.	1.6	90

#	ARTICLE	IF	CITATIONS
91	Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease. <i>ACS Omega</i> , 2020, 5, 33151-33161.	1.6	27
92	Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 616341.	1.6	83
93	Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics. <i>Pharmaceutics</i> , 2020, 12, 1247.	2.0	10
94	Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19. <i>Physical Chemistry Chemical Physics</i> , 2020, 22, 28115-28122.	1.3	39
95	Ruthenium-Catalyzed C-H Activations for the Synthesis of Indole Derivatives. <i>Catalysts</i> , 2020, 10, 1253.	1.6	17
96	Highlights in the fight against COVID-19: does autophagy play a role in SARS-CoV-2 infection?. <i>Autophagy</i> , 2020, 16, 2123-2127.	4.3	27
97	Computer aided identification of potential SARS CoV-2 main protease inhibitors from diterpenoids and biflavonoids of <i>Torreya nucifera</i> leaves. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2647-2662.	2.0	34
98	Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M ^{pro} and cathepsin L. <i>Science Advances</i> , 2020, 6, .	4.7	297
99	The Origin, Transmission, and Clinical Therapies in the Management of Coronavirus Diseases. <i>Methods in Pharmacology and Toxicology</i> , 2020, , 25-44.	0.1	1
100	SARS-CoV-2 Cysteine-like Protease Antibodies Can Be Detected in Serum and Saliva of COVID-19 Seropositive Individuals. <i>Journal of Immunology</i> , 2020, 205, 3130-3140.	0.4	32
101	Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1564-1581.	2.7	828
102	<i>In Silico</i> Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease. <i>Journal of Physical Chemistry Letters</i> , 2020, 11, 4413-4420.	2.1	118
103	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	6.6	1,387
104	Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19. <i>Life Sciences</i> , 2020, 256, 117963.	2.0	58
105	Repurposing cefuroxime for treatment of COVID-19: a scoping review of <i>in silico</i> studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 4547-4554.	2.0	35
106	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. <i>Cell Research</i> , 2020, 30, 678-692.	5.7	662
107	Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors an <i>in silico</i> docking and molecular dynamics simulation study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 4362-4374.	2.0	216
108	Topological analysis of SARS CoV-2 main protease. <i>Chaos</i> , 2020, 30, 061102.	1.0	47

#	ARTICLE	IF	CITATIONS
109	Recent Understandings Toward Coronavirus Disease 2019 (COVID-19): From Bench to Bedside. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 476.	1.8	27
110	Severe Acute Respiratory Syndrome Coronavirus 2: From Gene Structure to Pathogenic Mechanisms and Potential Therapy. <i>Frontiers in Microbiology</i> , 2020, 11, 1576.	1.5	32
111	Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative against SARS-CoV2: An In Silico Analysis. <i>Biomolecules</i> , 2020, 10, 954.	1.8	43
112	The SARS-CoV-2 main protease as drug target. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127377.	1.0	550
113	Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2. <i>Future Medicinal Chemistry</i> , 2020, 12, 1565-1578.	1.1	22
114	Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. <i>Virus Research</i> , 2020, 286, 198073.	1.1	35
115	Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. <i>Nature Communications</i> , 2020, 11, 3202.	5.8	334
116	Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2. <i>Advanced Science</i> , 2020, 7, 2001474.	5.6	14
117	Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 M ^{pro} by QM/MM computational methods. <i>Chemical Science</i> , 2020, 11, 10626-10630.	3.7	130
118	Emerging Prevention and Treatment Strategies to Control COVID-19. <i>Pathogens</i> , 2020, 9, 501.	1.2	22
119	Structural Basis of SARS-CoV-2 and SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 465-493.	4.2	36
120	Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development. <i>Asian Journal of Pharmaceutical Sciences</i> , 2021, 16, 4-23.	4.3	46
121	Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 M ^{pro} , using molecular docking and dynamics simulation studies. <i>European Journal of Pharmacology</i> , 2021, 890, 173664.	1.7	25
122	Quantum chemical insight into molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likeness and molecular docking of the novel anti COVID-19 molecule 2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]-N-(4-fluorophenyl)acetamide - dimer. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2021, 244, 118825.	2.0	26
123	Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2. <i>Phytomedicine</i> , 2021, 85, 153364.	2.3	102
124	DockCoV2: a drug database against SARS-CoV-2. <i>Nucleic Acids Research</i> , 2021, 49, D1152-D1159.	6.5	42
125	COVID-19: Discovery, diagnostics and drug development. <i>Journal of Hepatology</i> , 2021, 74, 168-184.	1.8	302
126	Why Does the Novel Coronavirus Spike Protein Interact so Strongly with the Human ACE2? A Thermodynamic Answer. <i>ChemBioChem</i> , 2021, 22, 865-875.	1.3	31

#	ARTICLE	IF	CITATIONS
127	Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 29, 115860.	1.4	126
128	Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12998.	1.3	201
129	Mechanism of inhibition of SARS-CoV-2 M ^{pro} by N3 peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity. <i>Chemical Science</i> , 2021, 12, 1433-1444.	3.7	87
130	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. <i>Medicinal Research Reviews</i> , 2021, 41, 1375-1426.	5.0	28
131	The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 63-71.	1.0	30
132	Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111035.	2.5	24
133	The future of covalent inhibition. <i>Annual Reports in Medicinal Chemistry</i> , 2021, 56, 267-284.	0.5	0
134	Potential inhibitors of SARS-CoV-2: recent advances. <i>Journal of Drug Targeting</i> , 2021, 29, 349-364.	2.1	27
135	Microsecond MD Simulation and Multiple-Conformation Virtual Screening to Identify Potential Anti-COVID-19 Inhibitors Against SARS-CoV-2 Main Protease. <i>Frontiers in Chemistry</i> , 2020, 8, 595273.	1.8	32
136	A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors**. <i>ChemMedChem</i> , 2021, 16, 942-948.	1.6	92
137	Potential SARS-CoV-2 main protease inhibitors. <i>Drug Discovery Today</i> , 2021, 26, 804-816.	3.2	128
138	Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease. <i>Journal of Molecular Liquids</i> , 2021, 322, 114999.	2.3	26
139	Recent Insights into Emerging Coronavirus: SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2021, 7, 1369-1388.	1.8	27
140	Protease inhibitors targeting the main protease and papain-like protease of coronaviruses. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 309-324.	2.4	25
141	Computer-aided approaches reveal trihydroxychroman and pyrazolone derivatives as potential inhibitors of SARS-CoV-2 virus main protease. <i>Acta Pharmaceutica</i> , 2021, 71, 325-333.	0.9	4
142	Eine Strategie zur Ligandenselektion identifiziert chemische Sonden für die Markierung von SARS-CoV-2-Proteasen. <i>Angewandte Chemie</i> , 2021, 133, 6874-6881.	1.6	2
143	A Ligand Selection Strategy Identifies Chemical Probes Targeting the Proteases of SARS-CoV-2. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 6799-6806.	7.2	14
144	In Silico Study of Coumarins and Quinolines Derivatives as Potent Inhibitors of SARS-CoV-2 Main Protease. <i>Frontiers in Chemistry</i> , 2020, 8, 595097.	1.8	28

#	ARTICLE	IF	CITATIONS
145	Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode. <i>Science Bulletin</i> , 2021, 66, 661-663.	4.3	41
146	Functional and druggability analysis of the SARS-CoV-2 proteome. <i>European Journal of Pharmacology</i> , 2021, 890, 173705.	1.7	34
147	The recent outbreaks of human coronaviruses: A medicinal chemistry perspective. <i>Medicinal Research Reviews</i> , 2021, 41, 72-135.	5.0	31
148	Severe acute respiratory syndromeâ€coronavirusâ€: Current advances in therapeutic targets and drug development. <i>Reviews in Medical Virology</i> , 2021, 31, e2174.	3.9	7
149	Structure of SARS-CoV-2 main protease in the apo state. <i>Science China Life Sciences</i> , 2021, 64, 656-659.	2.3	15
150	SARSâ€CoVâ€2: Mechanism of infection and emerging technologies for future prospects. <i>Reviews in Medical Virology</i> , 2021, 31, e2168.	3.9	28
151	History and Recent Advances in Coronavirus Discovery. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 3-24.	0.1	3
152	Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1722-1730.	1.7	40
153	Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. <i>Topics in Current Chemistry</i> , 2021, 379, 4.	3.0	15
154	Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 219-260.	0.8	5
155	One Year of SARS-CoV-2: How Much Has the Virus Changed?. <i>Biology</i> , 2021, 10, 91.	1.3	91
156	Zinc thiotropolone combinations as inhibitors of the SARS-CoV-2 main protease. <i>Dalton Transactions</i> , 2021, 50, 12226-12233.	1.6	7
157	What coronavirus 3Câ€like protease tells us: From structure, substrate selectivity, to inhibitor design. <i>Medicinal Research Reviews</i> , 2021, 41, 1965-1998.	5.0	73
158	Therapeutic targets and potential agents for the treatment of COVIDâ€19. <i>Medicinal Research Reviews</i> , 2021, 41, 1775-1797.	5.0	21
159	Computational analysis of dynamic allostery and control in the SARS-CoV-2 main protease. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20200591.	1.5	37
160	The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. <i>Nature Communications</i> , 2021, 12, 488.	5.8	196
161	Asymmetric dynamics of dimeric SARS-CoV-2 and SARS-CoV main proteases in an apo form: Molecular dynamics study on fluctuations of active site, catalytic dyad, and hydration water. <i>BBA Advances</i> , 2021, 1, 100016.	0.7	4
162	A phytochemical-based medication search for the SARS-CoV-2 infection by molecular docking models towards spike glycoproteins and main proteases. <i>RSC Advances</i> , 2021, 11, 12003-12014.	1.7	17

#	ARTICLE	IF	CITATIONS
163	Computational simulations on the binding and reactivity of a nitrile inhibitor of the SARS-CoV-2 main protease. <i>Chemical Communications</i> , 2021, 57, 9096-9099.	2.2	32
164	Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2537-2548.	1.9	18
165	A review on potential of natural products in the management of COVID-19. <i>RSC Advances</i> , 2021, 11, 16711-16735.	1.7	59
166	The role of chemical biology in the fight against SARS-CoV-2. <i>Biochemical Journal</i> , 2021, 478, 157-177.	1.7	2
167	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167
169	Molecular design of anticancer drugs from marine fungi derivatives. <i>RSC Advances</i> , 2021, 11, 20173-20179.	1.7	9
170	Protein Structure, Dynamics and Assembly: Implications for Drug Discovery. , 2021, , 91-122.		1
171	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <i>Frontiers in Physiology</i> , 2021, 12, 593223.	1.3	113
172	Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. <i>Annual Review of Microbiology</i> , 2021, 75, 19-47.	2.9	52
173	First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery. <i>Molecular Diversity</i> , 2021, 25, 1827-1838.	2.1	33
174	Drug repurposing and computational modeling for discovery of inhibitors of the main protease (M ^{pro}) of SARS-CoV-2. <i>RSC Advances</i> , 2021, 11, 23450-23458.	1.7	15
175	Ligand-based approach for predicting drug targets and for virtual screening against COVID-19. <i>Briefings in Bioinformatics</i> , 2021, 22, 1053-1064.	3.2	27
176	<i>In silico</i> and <i>in vitro</i> evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CL ^{pro}). <i>Phytotherapy Research</i> , 2021, 35, 2841-2845.	2.8	80
177	The Main Protease of SARS COV-2 and Its Specific Inhibitors. , 2021, , 121-147.		2
178	An overview of potential inhibitors targeting non-structural proteins 3 (PLpro and Mac1) and 5 (3CL ^{pro} /M ^{pro}) of SARS-CoV-2. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4868-4883.	1.9	39
179	Structures of SARS-CoV-2 RNA-Binding Proteins and Therapeutic Targets. <i>Intervirology</i> , 2021, 64, 55-68.	1.2	36
180	The immunodominant and neutralization linear epitopes for SARS-CoV-2. <i>Cell Reports</i> , 2021, 34, 108666.	2.9	65
181	Recent biotechnological advances as potential intervention strategies against COVID-19. <i>3 Biotech</i> , 2021, 11, 41.	1.1	10

#	ARTICLE	IF	CITATIONS
182	Binding of inhibitors to the monomeric and dimeric SARS-CoV-2 Mpro. RSC Advances, 2021, 11, 2926-2934.	1.7	19
183	Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-COV-2. Molecules, 2021, 26, 674.	1.7	27
184	Innate immune evasion mediated by picornaviral 3C protease: Possible lessons for coronaviral 3C-like protease?. Reviews in Medical Virology, 2021, 31, 1-22.	3.9	18
185	Computational estimation of potential inhibitors from known drugs against the main protease of SARS-CoV-2. RSC Advances, 2021, 11, 17478-17486.	1.7	17
186	Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. Viruses, 2021, 13, 174.	1.5	80
187	A Global Review on Short Peptides: Frontiers and Perspectives. Molecules, 2021, 26, 430.	1.7	190
188	Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease. Physical Chemistry Chemical Physics, 2021, 23, 6746-6757.	1.3	30
189	Covalent Antiviral Agents. Advances in Experimental Medicine and Biology, 2021, 1322, 285-312.	0.8	2
190	SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development. Expert Review of Clinical Pharmacology, 2021, 14, 225-237.	1.3	18
191	Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Frontiers in Pharmacology, 2020, 11, 630500.	1.6	32
193	Investigation of the inhibitory activity of some dietary bioactive flavonoids against SARS-CoV-2 using molecular dynamics simulations and MM-PBSA calculations. Journal of Biomolecular Structure and Dynamics, 2022, 40, 6755-6770.	2.0	10
194	Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19. ACS Infectious Diseases, 2021, 7, 1457-1468.	1.8	75
195	A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL ^{pro} Inhibitor PF-00835231 as a Potential New Treatment for COVID-19. Journal of Virology, 2021, 95, .	1.5	94
196	Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19). Emergent Materials, 2021, 4, 35-55.	3.2	19
197	A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. IScience, 2021, 24, 102021.	1.9	66
198	Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations. ACS Central Science, 2021, 7, 467-475.	5.3	182
199	De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning. BMC Chemistry, 2021, 15, 8.	1.6	49
200	Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Signal Transduction and Targeted Therapy, 2021, 6, 51.	7.1	20

#	ARTICLE	IF	CITATIONS
201	The Hydroalcoholic Extract of <i>Uncaria tomentosa</i> (Cat's Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-11.	0.5	16
203	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. <i>Frontiers in Immunology</i> , 2020, 11, 616595.	2.2	20
204	Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoV-2 Main Protease Inhibitors. <i>Molecules</i> , 2021, 26, 936.	1.7	16
205	Crystallographic models of SARS-CoV-2 3CL ^{pro} : in-depth assessment of structure quality and validation. <i>IUCr</i> , 2021, 8, 238-256.	1.0	21
206	Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	15
207	Deep Learning-Based Potential Ligand Prediction Framework for COVID-19 with Drug-Target Interaction Model. <i>Cognitive Computation</i> , 2021, , 1-13.	3.6	9
208	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. <i>Frontiers in Immunology</i> , 2021, 12, 631139.	2.2	117
209	Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2; Antiviral Screening and Molecular Docking Studies. <i>Pharmaceutics</i> , 2021, 13, 307.	2.0	28
210	Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses. <i>Molecules</i> , 2021, 26, 986.	1.7	60
211	COVID-19: Diagnostics, Therapeutic Advances, and Vaccine Development. <i>Current Clinical Microbiology Reports</i> , 2021, 8, 152-166.	1.8	15
212	Overview of antiviral drug candidates targeting coronaviral 3C ^{like} main proteases. <i>FEBS Journal</i> , 2021, 288, 5089-5121.	2.2	28
213	Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease. <i>Frontiers in Pharmacology</i> , 2021, 12, 636989.	1.6	28
214	A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease. <i>PLoS ONE</i> , 2021, 16, e0245962.	1.1	43
215	Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases. <i>Cell and Bioscience</i> , 2021, 11, 45.	2.1	47
216	Virtual screening and molecular dynamics simulation study of plant-derived compounds to identify potential inhibitors of main protease from SARS-CoV-2. <i>Briefings in Bioinformatics</i> , 2021, 22, 1402-1414.	3.2	75
217	Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2065.	1.8	3
218	Molecular Docking of Quinine Derivative as Inhibitor in Sars-Cov-2. <i>Journal of Physics: Conference Series</i> , 2021, 1819, 012053.	0.3	5
219	The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113157.	2.6	35

#	ARTICLE	IF	CITATIONS
220	Easy Synthesis of Complex Biomolecular Assemblies: Wheat Germ Cell-Free Protein Expression in Structural Biology. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 639587.	1.6	21
222	SARS-CoV-2 Genome from the Khyber Pakhtunkhwa Province of Pakistan. <i>ACS Omega</i> , 2021, 6, 6588-6599.	1.6	6
223	Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches. <i>Pharmaceuticals</i> , 2021, 14, 213.	1.7	45
224	Protein structural heterogeneity: A hypothesis for the basis of proteolytic recognition by the main protease of SARS-CoV and SARS-CoV-2. <i>Biochimie</i> , 2021, 182, 177-184.	1.3	10
225	A computational framework of host-based drug repositioning for broad-spectrum antivirals against RNA viruses. <i>IScience</i> , 2021, 24, 102148.	1.9	10
226	Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2. <i>Journal of Structural Biology</i> , 2021, 213, 107690.	1.3	8
227	A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1079-1095.	2.5	44
229	Repurposed Therapeutic Strategies towards COVID-19 Potential Targets Based on Genomics and Protein Structure Remodeling. , 0, , .		2
230	Multiscale Simulations of SARS-CoV-2 3CL Protease Inhibition with Aldehyde Derivatives. Role of Protein and Inhibitor Conformational Changes in the Reaction Mechanism. <i>ACS Catalysis</i> , 2021, 11, 4157-4168.	5.5	40
231	The Inhibitory Effects of Plant Derivate Polyphenols on the Main Protease of SARS Coronavirus 2 and Their Structure-Activity Relationship. <i>Molecules</i> , 2021, 26, 1924.	1.7	39
232	Identification of mutation resistance coldspots for targeting the SARS-CoV2 main protease. <i>IUBMB Life</i> , 2021, 73, 670-675.	1.5	30
233	Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 10423-10429.	7.2	95
234	SARS-CoV-2 M ^{pro} inhibitors with antiviral activity in a transgenic mouse model. <i>Science</i> , 2021, 371, 1374-1378.	6.0	324
236	Direct Observation of Protonation State Modulation in SARS-CoV-2 Main Protease upon Inhibitor Binding with Neutron Crystallography. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4991-5000.	2.9	36
237	Die Hauptprotease von SARS-CoV-2 als Zielstruktur: Von der Etablierung eines Hochdurchsatz-Screenings zum Design maßgeschneiderter Inhibitoren. <i>Angewandte Chemie</i> , 2021, 133, 10515-10521.	1.6	3
238	Exploration of Some Naturally Occurring Fungal-Derived Bioactive Molecules as Potential SARS-CoV-2 Main Protease (MPro) Inhibitors Through In-silico Approach. <i>Journal of Computational Biophysics and Chemistry</i> , 2021, 20, 251-266.	1.0	1
239	De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence. <i>Future Medicinal Chemistry</i> , 2021, 13, 575-585.	1.1	66
240	Recent Advances in the Discovery of Potent Proteases Inhibitors Targeting the SARS Coronaviruses. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 307-328.	1.0	4

#	ARTICLE	IF	CITATIONS
241	Drug discovery and development targeting the life cycle of SARS-CoV-2. <i>Fundamental Research</i> , 2021, 1, 151-165.	1.6	9
242	Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants. <i>Scientific Reports</i> , 2021, 11, 5543.	1.6	63
243	Precision therapeutic targets for COVID-19. <i>Virology Journal</i> , 2021, 18, 66.	1.4	40
244	Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates. <i>Bioscience Reports</i> , 2021, 41, .	1.1	16
245	Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	27
246	Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. <i>Frontiers in Chemistry</i> , 2021, 9, 622898.	1.8	213
247	Identification of natural compounds as potent inhibitors of SARS-CoV-2 main protease using combined docking and molecular dynamics simulations. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 2423-2431.	1.8	47
248	Highlights from a year in a pandemic. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	4
249	Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts. <i>Journal of Ethnopharmacology</i> , 2021, 270, 113869.	2.0	103
250	Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor. <i>Virology</i> , 2021, 556, 73-78.	1.1	24
251	Current diagnostic and therapeutic strategies for COVID-19. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 129-137.	2.4	11
252	Prevention of SARS-CoV-2 Proliferation with a Novel and Potent Main Protease Inhibitor by Docking, ADMET, MM-PBSA, and Molecular Dynamics Simulation. <i>Journal of Computational Biophysics and Chemistry</i> , 2021, 20, 305-322.	1.0	8
253	The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors. <i>Scientific Reports</i> , 2021, 11, 9283.	1.6	48
254	Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. <i>Topics in Current Chemistry</i> , 2021, 379, 23. Molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 I	3.0	6
255	(2E)-N-methyl-2-[(4-oxo-4H-chromen-3-yl)methylidene]-hydrazinecarbothioamide (Dimer) - quantum chemical approach. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2021, 251, 119388.	2.0	9
256	In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants. <i>Journal of Taibah University Medical Sciences</i> , 2021, 16, 162-176.	0.5	28
257	An Updated Review on SARS-CoV-2 Main Proteinase (MPro): Protein Structure and Small-Molecule Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 442-460.	1.0	30
258	Benchmark of Popular Free Energy Approaches Revealing the Inhibitors Binding to SARS-CoV-2 Mpro. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 2302-2312.	2.5	66

#	ARTICLE	IF	CITATIONS
259	Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation. <i>PeerJ</i> , 2021, 9, e11261.	0.9	24
260	Binding ability of arginine, citrulline, N-acetyl citrulline and thiocitrulline with SARS COV-2 main protease using molecular docking studies. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2021, 10, 28.	1.2	1
261	Development of a chiral HPLC method for the separation and quantification of hydroxychloroquine enantiomers. <i>Scientific Reports</i> , 2021, 11, 8017.	1.6	10
262	A Non-Linear Biostatistical Graphical Modeling of Preventive Actions and Healthcare Factors in Controlling COVID-19 Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4491.	1.2	12
263	The Computational Intervention of Macrolide Antibiotics in the Treatment of COVID-19. <i>Current Pharmaceutical Design</i> , 2021, 27, 1202-1210.	0.9	7
264	Structural insights into SARS-CoV-2 infection and therapeutics development. <i>Stem Cell Research</i> , 2021, 52, 102219.	0.3	7
265	SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models. <i>Frontiers in Pharmacology</i> , 2021, 12, 638334.	1.6	14
267	Inhibition of SARS-CoV-2 main protease: a repurposing study that targets the dimer interface of the protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 7167-7182.	2.0	5
268	Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?. <i>European Journal of Medicinal Chemistry</i> , 2021, 215, 113294.	2.6	26
269	In-Silico Structure-Based Drug Discovery of Candidate Drugs against Novel Protein Receptor Complex Nsp10-Nsp16 of SARS-CoV-2 using Drug Repurposing Approach. <i>Coronaviruses</i> , 2021, 2, 255-264.	0.2	1
271	SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. <i>Biomolecules</i> , 2021, 11, 607.	1.8	97
272	The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 505-518.	1.9	20
273	Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2794-2808.	2.9	52
274	Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. <i>Nature Communications</i> , 2021, 12, 2016.	5.8	65
275	Molecular modeling-guided optimization of acetylcholinesterase reactivators: A proof for reactivation of covalently inhibited targets. <i>European Journal of Medicinal Chemistry</i> , 2021, 215, 113286.	2.6	2
276	Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling. <i>Frontiers in Pharmacology</i> , 2021, 12, 643857.	1.6	20
277	Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For. <i>Journal of Thoracic Oncology</i> , 2021, 16, 546-571.	0.5	25
278	Elucidation of Cryptic and Allosteric Pockets within the SARS-CoV-2 Main Protease. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 3495-3501.	2.5	51

#	ARTICLE	IF	CITATIONS
279	Scrutinizing Coronaviruses Using Publicly Available Bioinformatic Tools: The Viral Structural Proteins as a Case Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671923.	1.6	0
280	Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replication. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 8464-8493.	2.0	4
281	Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 8925-8937.	2.0	8
282	Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach. <i>Journal of Molecular Liquids</i> , 2021, 330, 115636.	2.3	10
283	Reckoning $\hat{1}^3$ -Glutamyl-S-allylcysteine as a potential main protease (m ^{pro}) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation. <i>Drug Development and Industrial Pharmacy</i> , 2021, 47, 699-710.	0.9	8
284	Therapeutic approaches for SARS-CoV-2 infection. <i>Methods</i> , 2021, 195, 29-43.	1.9	14
285	Discovery of novel inhibitors against main protease (M ^{pro}) of SARS-CoV-2 via virtual screening and biochemical evaluation. <i>Bioorganic Chemistry</i> , 2021, 110, 104767.	2.0	21
286	In silico structural elucidation of the rabies RNA-dependent RNA polymerase (RdRp) toward the identification of potential rabies virus inhibitors. <i>Journal of Molecular Modeling</i> , 2021, 27, 183.	0.8	1
287	COVID-19 and cardiovascular complications – the preliminary results of the LATE-COVID study. <i>Archives of Medical Science</i> , 2021, 17, 818-822.	0.4	39
288	Robust classification-based molecular modelling of diverse chemical entities as potential SARS-CoV-2 3CL ^{pro} inhibitors: theoretical justification in light of experimental evidences. <i>SAR and QSAR in Environmental Research</i> , 2021, 32, 473-493.	1.0	9
289	ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model. <i>Biochemical and Biophysical Research Communications</i> , 2021, 555, 134-139.	1.0	30
290	Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 166-172.	1.3	19
291	An update review of emerging small-molecule therapeutic options for COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111313.	2.5	52
292	Graphene Oxide Nanosheets Interact and Interfere with SARS-CoV-2 Surface Proteins and Cell Receptors to Inhibit Infectivity. <i>Small</i> , 2021, 17, e2101483.	5.2	46
293	Binding mode characterization of 13b in the monomeric and dimeric states of SARS-CoV-2 main protease using molecular dynamics simulations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 9287-9305.	2.0	12
294	In silico screening of potent bioactive compounds from honeybee products against COVID-19 target enzymes. <i>Environmental Science and Pollution Research</i> , 2021, 28, 40507-40514.	2.7	48
295	Current Strategies of Antiviral Drug Discovery for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671263.	1.6	75
296	Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 628585.	1.6	31

#	ARTICLE	IF	CITATIONS
297	<i>In silico</i> Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives. <i>Molecular Informatics</i> , 2021, 40, e2100028.	1.4	33
298	Interaction of small molecules with the SARS-CoV-2 papain-like protease: <i>In silico</i> studies and <i>in vitro</i> validation of protease activity inhibition using an enzymatic inhibition assay. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 104, 107851.	1.3	29
299	Isolation and <i>In Silico</i> Anti-COVID-19 Main Protease (Mpro) Activities of Flavonoids and a Sesquiterpene Lactone from <i>Artemisia sublessingiana</i> . <i>Journal of Chemistry</i> , 2021, 2021, 1-8.	0.9	22
300	The Contribution of Biophysics and Structural Biology to Current Advances in COVID-19. <i>Annual Review of Biophysics</i> , 2021, 50, 493-523.	4.5	12
301	Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics. <i>Molecules</i> , 2021, 26, 2654.	1.7	36
302	Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. <i>Nature Communications</i> , 2021, 12, 3061.	5.8	149
303	Benchmarking the Ability of Common Docking Programs to Correctly Reproduce and Score Binding Modes in SARS-CoV-2 Protease Mpro. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 2957-2966.	2.5	50
304	Virtual screening for small molecular non-covalent binders of the SARS-CoV-2 main protease. <i>Archives of Medical Science</i> , 2021, 17, 838-842.	0.4	0
305	Flavonoids are promising safe therapy against COVID-19. <i>Phytochemistry Reviews</i> , 2022, 21, 291-312.	3.1	87
306	Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111232.	2.5	7
308	Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease. <i>Frontiers in Chemistry</i> , 2021, 9, 692168.	1.8	75
309	Interfering with the Reactive Cysteine Proteome in COVID-19. <i>Current Medicinal Chemistry</i> , 2022, 29, 1657-1663.	1.2	2
310	Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. <i>Nature Communications</i> , 2021, 12, 3623.	5.8	111
311	Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. <i>Antiviral Research</i> , 2021, 190, 105075.	1.9	44
312	Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity. <i>Journal of Virology</i> , 2021, 95, e0237420.	1.5	27
313	COVID-19: Innovative Antiviral Drugs Required for Long-Term Prevention and Control of Coronavirus Diseases. <i>Current Medicinal Chemistry</i> , 2021, 28, 3554-3567.	1.2	2
314	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). <i>BioMed Research International</i> , 2021, 2021, 1-20.	0.9	13
315	A Multidisciplinary Approach to Coronavirus Disease (COVID-19). <i>Molecules</i> , 2021, 26, 3526.	1.7	14

#	ARTICLE	IF	CITATIONS
316	An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19. <i>BioMed Research International</i> , 2021, 2021, 1-18.	0.9	95
317	Therapeutic Potential of Glycosyl Flavonoids as Anti-Coronaviral Agents. <i>Pharmaceuticals</i> , 2021, 14, 546.	1.7	18
318	Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 42, 128067.	1.0	5
319	Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists. <i>European Journal of Medicinal Chemistry</i> , 2021, 218, 113390.	2.6	24
320	Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2. <i>Chemical Physics Impact</i> , 2021, 2, 100011.	1.7	18
321	Science's Response to CoVID-19. <i>ChemMedChem</i> , 2021, 16, 2288-2314.	1.6	15
322	Identification of Naturally Occurring Antiviral Molecules for SARS-CoV-2 Mitigation. <i>The Open Covid Journal</i> , 2021, 1, 38-46.	0.4	7
323	Efficiency Improvements and Discovery of New Substrates for a SARS-CoV-2 Main Protease FRET Assay. <i>SLAS Discovery</i> , 2021, 26, 1189-1199.	1.4	14
324	Dynamic Profiling of \hat{P}^2 -Coronavirus 3CL M ^{pro} Protease Ligand-Binding Sites. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 3058-3073.	2.5	35
325	Virtual screening of peptides with high affinity for SARS-CoV-2 main protease. <i>Computers in Biology and Medicine</i> , 2021, 133, 104363.	3.9	5
326	De novo ssRNA Aptamers against the SARS-CoV-2 Main Protease: In Silico Design and Molecular Dynamics Simulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6874.	1.8	8
327	Food Containing Bioactive Flavonoids and Other Phenolic or Sulfur Phytochemicals With Antiviral Effect: Can We Design a Promising Diet Against COVID-19?. <i>Frontiers in Nutrition</i> , 2021, 8, 661331.	1.6	20
328	Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review. <i>Tissue and Cell</i> , 2021, 70, 101497.	1.0	33
329	Search for Non-Protein Protease Inhibitors Constituted with an Indole and Acetylene Core. <i>Molecules</i> , 2021, 26, 3817.	1.7	6
330	Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. <i>ACS Central Science</i> , 2021, 7, 1245-1260.	5.3	115
331	SARS-CoV-2: Origin, Evolution, and Targeting Inhibition. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 676451.	1.8	21
332	Myricetin Inhibits SARS-CoV-2 Viral Replication by Targeting Mpro and Ameliorates Pulmonary Inflammation. <i>Frontiers in Pharmacology</i> , 2021, 12, 669642.	1.6	58
333	Plant-Based Phytochemical Screening by Targeting Main Protease of SARS-CoV-2 to Design Effective Potent Inhibitors. <i>Biology</i> , 2021, 10, 589.	1.3	46

#	ARTICLE	IF	CITATIONS
334	Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 Mpro. Signal Transduction and Targeted Therapy, 2021, 6, 214.	7.1	17
335	Scaffold Hopping of Î±-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 MPro Inhibitor. Pharmaceuticals, 2021, 14, 541.	1.7	17
336	New insights into the catalytic mechanism of the SARS-CoV-2 main protease: an ONIOM QM/MM approach. Molecular Diversity, 2022, 26, 1373-1381.	2.1	17
337	SARS-CoV-2 and hypertension. Physiological Reports, 2021, 9, e14800.	0.7	11
338	Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification. Journal of Ethnopharmacology, 2021, 273, 113871.	2.0	23
339	Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CLpro and PLpro". Journal of Molecular Structure, 2021, 1233, 130094.	1.8	17
340	Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib. ACS Omega, 2021, 6, 16584-16591.	1.6	17
342	SARS-CoV-2 Antiviral Therapy. Clinical Microbiology Reviews, 2021, 34, e0010921.	5.7	64
343	MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L**. ChemMedChem, 2022, 17, .	1.6	41
344	Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals. Bioorganic Chemistry, 2021, 112, 104889.	2.0	46
345	Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CLpro. International Journal of Biological Macromolecules, 2021, 183, 182-192.	3.6	22
346	Supramolecular Cylinders Target Bulge Structures in the 5' UTR of the RNA Genome of SARS-CoV-2 and Inhibit Viral Replication**. Angewandte Chemie - International Edition, 2021, 60, 18144-18151.	7.2	12
347	Interaction of selected terpenoids with two SARS-CoV-2 key therapeutic targets: An in silico study through molecular docking and dynamics simulations. Computers in Biology and Medicine, 2021, 134, 104538.	3.9	25
349	Advances in the computational landscape for repurposed drugs against COVID-19. Drug Discovery Today, 2021, 26, 2800-2815.	3.2	19
351	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharmaceutica Sinica B, 2022, 12, 1591-1623.	5.7	57
352	The interaction of the bioflavonoids with five SARS-CoV-2 proteins targets: An in silico study. Computers in Biology and Medicine, 2021, 134, 104464.	3.9	9
353	A fast protein binding site comparison algorithm for proteome-wide protein function prediction and drug repurposing. Proteins: Structure, Function and Bioinformatics, 2021, 89, 1541-1556.	1.5	9
354	Supramolecular Cylinders Target Bulge Structures in the 5' UTR of the RNA Genome of SARS-CoV-2 and Inhibit Viral Replication**. Angewandte Chemie, 2021, 133, 18292-18299.	1.6	3

#	ARTICLE	IF	CITATIONS
355	In Silico Design of Peptide-Based SARS-CoV-2 Fusion Inhibitors That Target WT and Mutant Versions of SARS-CoV-2 HR1 Domains. <i>Biophysica</i> , 2021, 1, 311-327.	0.6	8
356	Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. <i>Biochemical Pharmacology</i> , 2021, 189, 114424.	2.0	27
357	3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2926-2939.	2.9	75
358	In silico investigation of potential inhibitors to main protease and spike protein of SARS-CoV-2 in propolis. <i>Biochemistry and Biophysics Reports</i> , 2021, 26, 100969.	0.7	21
359	Production of Proteins of the SARS-CoV-2 Proteome for Drug Discovery. <i>ACS Omega</i> , 2021, 6, 19983-19994.	1.6	6
360	A Fungal Defensin Targets the SARS-CoV-2 Spike Receptor Binding Domain. <i>Journal of Fungi (Basel)</i> , 2021, 7, 114.	1.5	12
361	Coronavirus Porcine Epidemic Diarrhea Virus Nucleocapsid Protein Interacts with p53 To Induce Cell Cycle Arrest in S-Phase and Promotes Viral Replication. <i>Journal of Virology</i> , 2021, 95, e0018721.	1.5	34
362	Peptidomimetic β -Acylloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and <i>in Vitro</i> Biological Stability. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2905-2925.	2.9	71
363	Quantum simulations of SARS-CoV-2 main protease M ^{pro} enable high-quality scoring of diverse ligands. <i>Journal of Computer-Aided Molecular Design</i> , 2021, 35, 963-971.	1.3	13
364	Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. <i>Science</i> , 2021, 373, 931-936.	6.0	173
365	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. <i>International Immunopharmacology</i> , 2021, 96, 107763.	1.7	35
366	Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10047-10058.	2.9	38
367	Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	61
368	Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 M ^{pro} . <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 3917-3926.	2.5	52
369	Rational design of flavonoid based potential inhibitors targeting SARS-CoV 3CL protease for the treatment of COVID-19. <i>Journal of Molecular Structure</i> , 2021, 1237, 130380.	1.8	12
370	Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9057.	1.8	14
371	Targeting Some Enzymes with Repurposing Approved Pharmaceutical Drugs for Expedient Antiviral Approaches Against Newer Strains of COVID-19. <i>AAPS PharmSciTech</i> , 2021, 22, 214.	1.5	5
372	Comprehensive Analysis of SARS-COV-2 Drug Targets and Pharmacological Aspects in Treating the COVID-19. <i>Current Molecular Pharmacology</i> , 2022, 15, 393-417.	0.7	6

#	ARTICLE	IF	CITATIONS
373	Putative Role of Vitamin D for COVID-19 Vaccination. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8988.	1.8	32
374	Potential protective mechanisms of green tea polyphenol EGCG against COVID-19. <i>Trends in Food Science and Technology</i> , 2021, 114, 11-24.	7.8	96
375	Unmasking of crucial structural fragments for coronavirus protease inhibitors and its implications in COVID-19 drug discovery. <i>Journal of Molecular Structure</i> , 2021, 1237, 130366.	1.8	6
376	Sterenin M as a potential inhibitor of SARS-CoV-2 main protease identified from MeFSAT database using molecular docking, molecular dynamics simulation and binding free energy calculation. <i>Computers in Biology and Medicine</i> , 2021, 135, 104568.	3.9	22
377	Vitamin D and lumisterol novel metabolites can inhibit SARS-CoV-2 replication machinery enzymes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E246-E251.	1.8	38
378	Predicting the Relative Binding Affinity for Reversible Covalent Inhibitors by Free Energy Perturbation Calculations. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4733-4744.	2.5	9
379	Improved Synthesis of a Cyclic Glutamine Analogue Used in Antiviral Agents Targeting 3C and 3CL Proteases Including SARS-CoV-2 Mpro. <i>Journal of Organic Chemistry</i> , 2021, 86, 13104-13110.	1.7	8
380	Exploring peptide studies related to SARS-CoV to accelerate the development of novel therapeutic and prophylactic solutions against COVID-19. <i>Journal of Infection and Public Health</i> , 2021, 14, 1106-1119.	1.9	4
381	Near-physiological-temperature serial crystallography reveals conformations of SARS-CoV-2 main protease active site for improved drug repurposing. <i>Structure</i> , 2021, 29, 1382-1396.e6.	1.6	28
382	The impact of high-resolution structural data on stemming the COVID-19 pandemic. <i>Current Opinion in Virology</i> , 2021, 49, 127-138.	2.6	2
383	Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL ^{pro}). <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2880-2904.	2.9	78
384	The current state of validated small molecules inhibiting SARS-CoV-2 nonstructural proteins. <i>Turkish Journal of Biology</i> , 2021, 45, 469-483.	2.1	1
386	Molecular mechanism of anti-SARS-CoV2 activity of Ashwagandha-derived withanolides. <i>International Journal of Biological Macromolecules</i> , 2021, 184, 297-312.	3.6	30
387	Ugonin J Acts as a SARS-CoV-2 3C-like Protease Inhibitor and Exhibits Anti-inflammatory Properties. <i>Frontiers in Pharmacology</i> , 2021, 12, 720018.	1.6	11
388	Reducing SARS-CoV-2 pathological protein activity with small molecules. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 383-397.	2.4	11
389	Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease. <i>ACS Infectious Diseases</i> , 2021, 7, 2591-2595.	1.8	55
390	Theobroma cacao L. compounds: Theoretical study and molecular modeling as inhibitors of main SARS-CoV-2 protease. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111764.	2.5	17
391	Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. <i>Current Opinion in Virology</i> , 2021, 49, 36-40.	2.6	100

#	ARTICLE	IF	CITATIONS
392	Construction of a Noninfectious SARS-CoV-2 Replicon for Antiviral-Drug Testing and Gene Function Studies. <i>Journal of Virology</i> , 2021, 95, e0068721.	1.5	25
393	Inhibition of Cysteine Proteases by 6,6- ϵ^2 -Dihydroxythiobinupharidine (DTBN) from <i>Nuphar lutea</i> . <i>Molecules</i> , 2021, 26, 4743.	1.7	3
394	Phytomolecules Repurposed as Covid-19 Inhibitors: Opportunity and Challenges. <i>Current Microbiology</i> , 2021, 78, 3620-3633.	1.0	9
395	The Promising Enzymes for Inhibitors Development against COVID-19. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, .	1.1	0
396	Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9124.	1.8	76
397	Could Probiotics and Postbiotics Function as "Silver Bullet" in the Post-COVID-19 Era?. <i>Probiotics and Antimicrobial Proteins</i> , 2021, 13, 1499-1507.	1.9	12
398	Venetoclax: a promising repurposed drug against SARS-CoV-2 main protease. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 12088-12099.	2.0	3
399	Non-competitive interactions between hydroxychloroquine and azithromycin: Systematic density functional, molecular dynamics, and docking calculations. <i>Chemical Physics Letters</i> , 2021, 777, 138745.	1.2	5
400	Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 581-599.	5.7	33
401	Molecular Docking Analysis of the Phytochemicals from <i>Tinospora Cordifolia</i> as Potential Inhibitor Against Multi Targeted SARS-CoV-2 & Cytokine Storm. <i>Journal of Computational Biophysics and Chemistry</i> , 2021, 20, 559-580.	1.0	2
402	Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease. <i>Structure</i> , 2021, 29, 823-833.e5.	1.6	43
403	Exploring the SARS-Cov-2 Main Protease (Mpro) and RdRp Targets by Updating Current Structure-based Drug Design Utilizing Co-crystals to Combat COVID-19. <i>Current Drug Targets</i> , 2022, 23, 802-817.	1.0	2
404	Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2866-2879.	2.9	59
406	Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 140-147.	1.3	35
407	Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103315.	2.3	48
408	Discovery of novel inhibitors of SARS-CoV-2 main protease. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 12526-12534.	2.0	2
409	On the Origin of the Different Reversible Characters of Salinosporamide A and Homosalinosporamide A in the Covalent Inhibition of the Human 20S Proteasome. <i>ACS Catalysis</i> , 2021, 11, 11806-11819.	5.5	5
410	Evaluation of Inhibitory Activity In Silico of In-House Thiomorpholine Compounds between the ACE2 Receptor and S1 Subunit of SARS-CoV-2 Spike. <i>Pathogens</i> , 2021, 10, 1208.	1.2	0

#	ARTICLE	IF	CITATIONS
411	In Silico Prediction of Novel Inhibitors of SARS-CoV-2 Main Protease through Structure-Based Virtual Screening and Molecular Dynamic Simulation. <i>Pharmaceuticals</i> , 2021, 14, 896.	1.7	21
412	Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. <i>PLoS Pathogens</i> , 2021, 17, e1009898.	2.1	25
413	22-Hydroxyhopane, a novel multitargeted phytochemical against SARS-CoV-2 from <i>Adiantum latifolium</i> Lam. <i>Natural Product Research</i> , 2021, , 1-6.	1.0	6
414	Molecular docking studies of HIV TAT and sitagliptin nano-formula as potential therapeutic targeting SARS-CoV2 protease. <i>Journal of the Indian Chemical Society</i> , 2021, 98, 100119.	1.3	0
415	Special Features of COVID-19 in the FMOB: Fragment Molecular Orbital Calculations and Interaction Energy Analysis of SARS-CoV-2-Related Proteins. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4594-4612.	2.5	10
416	Effects of different corticosteroid therapy on severe COVID-19 patients: a meta-analysis of randomized controlled trials. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 79-89.	1.0	7
417	A Novel Class of Norovirus Inhibitors Targeting the Viral Protease with Potent Antiviral Activity In Vitro and In Vivo. <i>Viruses</i> , 2021, 13, 1852.	1.5	7
418	Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms. , 2021, 225, 107843.		258
419	Rapid structure-based identification of potential SARS-CoV-2 main protease inhibitors. <i>Future Medicinal Chemistry</i> , 2021, 13, 1435-1450.	1.1	9
420	Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium. <i>PLoS ONE</i> , 2021, 16, e0257784.	1.1	20
421	NMR spectroscopy of the main protease of SARS-CoV-2 and fragment-based screening identify three protein hotspots and an antiviral fragment. <i>Angewandte Chemie</i> , 2021, 133, 25632.	1.6	2
422	Host metabolic reprogramming in response to SARS-CoV-2 infection: A systems biology approach. <i>Microbial Pathogenesis</i> , 2021, 158, 105114.	1.3	44
423	Janus All-Cis-2,3,4,5,6-Pentafluorocyclohexyl Building Blocks Applied to Medicinal Chemistry and Bioactives Discovery Chemistry. <i>Chemistry - A European Journal</i> , 2021, 27, 16000-16005.	1.7	11
424	Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 23492-23494.	7.2	17
425	Crystal structures of human coronavirus NL63 main protease at different pH values. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2021, 77, 348-355.	0.4	3
426	Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease. <i>Angewandte Chemie</i> , 2021, 133, 23684-23686.	1.6	0
427	Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies. <i>Molecular Biomedicine</i> , 2021, 2, 28.	1.7	10
428	Screening of cryptogamic secondary metabolites as putative inhibitors of SARS-CoV-2 main protease and ribosomal binding domain of spike glycoprotein by molecular docking and molecular dynamics approaches. <i>Journal of Molecular Structure</i> , 2021, 1240, 130506.	1.8	12

#	ARTICLE	IF	CITATIONS
429	Structural biology of SARS-CoV-2 and implications for therapeutic development. <i>Nature Reviews Microbiology</i> , 2021, 19, 685-700.	13.6	259
430	Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and in silico COVID-19 drug candidate molecules. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 53-64.	1.8	10
431	Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 Mpro. <i>Molecular Diversity</i> , 2022, 26, 1645-1661.	2.1	6
432	Addressing the "hypoxia paradox"™ in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues. <i>Molecular Medicine</i> , 2021, 27, 120.	1.9	9
433	Separable Microneedle Patch to Protect and Deliver DNA Nanovaccines Against COVID-19. <i>ACS Nano</i> , 2021, 15, 14347-14359.	7.3	73
434	Repurposing the antibacterial drugs for inhibition of SARS-CoV2-PLpro using molecular docking, MD simulation and binding energy calculation. <i>Molecular Diversity</i> , 2022, 26, 2189-2209.	2.1	8
435	NMR Spectroscopy of the Main Protease of SARS-CoV-2 and Fragment-Based Screening Identify Three Protein Hotspots and an Antiviral Fragment. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 25428-25435.	7.2	22
436	A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 48, 128263.	1.0	20
437	Viral 3CLpro as a Target for Antiviral Intervention Using Milk-Derived Bioactive Peptides. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 2703-2716.	0.9	10
438	Structure-Based Discovery and Structural Basis of a Novel Broad-Spectrum Natural Product against the Main Protease of Coronavirus. <i>Journal of Virology</i> , 2022, 96, JVI0125321.	1.5	20
439	Inhibition Mechanism of SARS-CoV-2 Main Protease with Ketone-Based Inhibitors Unveiled by Multiscale Simulations. Insights for Improved Designs. <i>Angewandte Chemie</i> , 0, , .	1.6	0
440	Sub-Micromolar Inhibition of SARS-CoV-2 3CLpro by Natural Compounds. <i>Pharmaceuticals</i> , 2021, 14, 892.	1.7	16
441	SARS-COV-2 M ^{pro} conformational changes induced by covalently bound ligands. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 12347-12357.	2.0	15
442	Local topology and bifurcation hot-spots in proteins with SARS-CoV-2 spike protein as an example. <i>PLoS ONE</i> , 2021, 16, e0257886.	1.1	1
443	Inhibition Mechanism of SARS-CoV-2 Main Protease with Ketone-Based Inhibitors Unveiled by Multiscale Simulations: Insights for Improved Designs**. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 25933-25941.	7.2	24
444	Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies. <i>European Journal of Medicinal Chemistry</i> , 2021, 222, 113584.	2.6	57
445	A cyclic peptide inhibitor of the SARS-CoV-2 main protease. <i>European Journal of Medicinal Chemistry</i> , 2021, 221, 113530.	2.6	22
446	Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 50, 128333.	1.0	26

#	ARTICLE	IF	CITATIONS
447	Protein engineering design from directed evolution to de novo synthesis. <i>Biochemical Engineering Journal</i> , 2021, 174, 108096.	1.8	24
448	Recent progress in covalent warheads for in vivo targeting of endogenous proteins. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 47, 116386.	1.4	26
449	Rooibos, a supportive role to play during the COVID-19 pandemic?. <i>Journal of Functional Foods</i> , 2021, 86, 104684.	1.6	7
450	Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease. <i>Bioorganic Chemistry</i> , 2021, 116, 105363.	2.0	10
451	A short survey of dengue protease inhibitor development in the past 6 years (2015–2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 49, 116415.	1.4	10
452	Neutron crystallography for the elucidation of enzyme catalysis. <i>Current Opinion in Structural Biology</i> , 2021, 71, 36-42.	2.6	9
453	Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113789.	2.6	25
454	Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113863.	2.6	22
455	3CLpro and PLpro affinity, a docking study to fight COVID19 based on 900 compounds from PubChem and literature. Are there new drugs to be found?. <i>Journal of Molecular Structure</i> , 2021, 1245, 130968.	1.8	15
456	Virus structure and structure-based antivirals. <i>Current Opinion in Virology</i> , 2021, 51, 16-24.	2.6	9
457	Evaluating anti-coronavirus activity of some phosphoramides and their influencing inhibitory factors using molecular docking, DFT, QSAR, and NCI-RDG studies. <i>Journal of Molecular Structure</i> , 2022, 1248, 131481.	1.8	29
458	Computational strategies towards developing novel SARS-CoV-2 Mpro inhibitors against COVID-19. <i>Journal of Molecular Structure</i> , 2022, 1247, 131378.	1.8	11
459	Viral Proteases. , 2021, , 1-9.		0
460	Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4684-4701.	1.9	27
461	A review of the latest research on M ^{pro} targeting SARS-COV inhibitors. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1026-1036.	1.7	37
462	Dinitrosyl iron complexes (DNICs) as inhibitors of the SARS-CoV-2 main protease. <i>Chemical Communications</i> , 2021, 57, 8352-8355.	2.2	9
463	Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus. <i>Results in Chemistry</i> , 2021, 3, 100087.	0.9	14
464	Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease. <i>Chemical Science</i> , 2021, 12, 1513-1527.	3.7	47

#	ARTICLE	IF	CITATIONS
465	Perspectives for antivirals to limit SARS-CoV-2 infection (COVID-19). <i>Microbiology Australia</i> , 2021, 42, 47.	0.1	2
466	A critical overview of computational approaches employed for COVID-19 drug discovery. <i>Chemical Society Reviews</i> , 2021, 50, 9121-9151.	18.7	128
467	Electrostatic features for nucleocapsid proteins of SARS-CoV and SARS-CoV-2. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 2372-2383.	1.0	8
468	Allosteric inhibition of SARS-CoV-2 3CL protease by colloidal bismuth subcitrate. <i>Chemical Science</i> , 2021, 12, 14098-14102.	3.7	19
470	Diagnostic, Prognostic, and Therapeutic Use of Radiopharmaceuticals in the Context of SARS-CoV-2. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1-7.	2.5	6
471	Recent progress in the development of potential drugs against SARS-CoV-2. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100057.	1.7	7
472	Development and application of therapeutic antibodies against COVID-19. <i>International Journal of Biological Sciences</i> , 2021, 17, 1486-1496.	2.6	47
473	SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species. <i>Emerging Microbes and Infections</i> , 2021, 10, 178-195.	3.0	178
474	<i>Scutellaria baicalensis</i> extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease <i>in vitro</i> . <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 497-503.	2.5	206
475	Proposing high-affinity inhibitors from <i>Glycyrrhiza glabra</i> L. against SARS-CoV-2 infection: virtual screening and computational analysis. <i>New Journal of Chemistry</i> , 2021, 45, 15977-15995.	1.4	14
476	A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design. <i>Chemical Science</i> , 2021, 12, 3489-3496.	3.7	40
477	Evolutionary Multi-objective Design of SARS-CoV-2 Protease Inhibitor Candidates. <i>Lecture Notes in Computer Science</i> , 2020, , 357-371.	1.0	5
478	An Overview of the Crystallized Structures of the SARS-CoV-2. <i>Protein Journal</i> , 2020, 39, 600-618.	0.7	32
479	Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. <i>Bioorganic Chemistry</i> , 2020, 104, 104269.	2.0	74
480	COVID-19 therapy: What weapons do we bring into battle?. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115757.	1.4	22
481	Unraveling the SARS-CoV-2 Main Protease Mechanism Using Multiscale Methods. <i>ACS Catalysis</i> , 2020, 10, 12544-12554.	5.5	107
482	Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing. <i>ACS Nano</i> , 2021, 15, 857-872.	7.3	38
483	The sprint to solve coronavirus protein structures and disarm them with drugs. <i>Nature</i> , 2020, 581, 252-255.	13.7	30

#	ARTICLE	IF	CITATIONS
484	Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19). RSC Advances, 2020, 10, 40867-40875.	1.7	17
485	A pocket guide on how to structure SARS-CoV-2 drugs and therapies. Biochemical Society Transactions, 2020, 48, 2625-2641.	1.6	10
486	Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality. Journal of Cell Biology, 2020, 219, .	2.3	20
487	The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. Briefings in Bioinformatics, 2021, 22, 742-768.	3.2	29
488	Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach. Briefings in Bioinformatics, 2021, 22, 1346-1360.	3.2	62
521	Room-temperature X-ray crystallography reveals the oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL M ^{pro} : insights into enzyme mechanism and drug design. IUCr, 2020, 7, 1028-1035.	1.0	49
522	Computational screening for potential drug candidates against the SARS-CoV-2 main protease. F1000Research, 2020, 9, 514.	0.8	12
523	Computational screening for potential drug candidates against the SARS-CoV-2 main protease. F1000Research, 2020, 9, 514.	0.8	10
524	Fractional-Order Susceptible-Infected Model: Definition and Applications to the Study of COVID-19 Main Protease. Fractional Calculus and Applied Analysis, 2020, 23, 635-655.	1.2	13
526	Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2. Current Topics in Medicinal Chemistry, 2020, 20, 2362-2378.	1.0	6
527	Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery. Current Topics in Medicinal Chemistry, 2020, 20, 1423-1433.	1.0	36
528	Computational studies of drugs for possible action against Covid-19 infections. Journal of Drug Delivery and Therapeutics, 2020, 10, 99-105.	0.2	3
531	Blocking Effect of Demethylzeylasteral on the Interaction between Human ACE2 Protein and SARS-CoV-2 RBD Protein Discovered Using SPR Technology. Molecules, 2021, 26, 57.	1.7	27
532	An overview of potential therapeutic agents to treat COVID-19. BioScience Trends, 2020, 14, 318-327.	1.1	5
533	Computational anti-COVID-19 drug design: progress and challenges. Briefings in Bioinformatics, 2022, 23, .	3.2	8
534	The role of vitamin B12 in viral infections: a comprehensive review of its relationship with the muscle-gut-brain axis and implications for SARS-CoV-2 infection. Nutrition Reviews, 2022, 80, 561-578.	2.6	31
535	Development of a Novel Pharmacophore Model Guided by the Ensemble of Waters and Small Molecule Fragments Bound to SARS-CoV-2 Main Protease. Molecular Informatics, 2022, 41, e2100178.	1.4	3
536	Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166294.	1.8	28

#	ARTICLE	IF	CITATIONS
537	High predictive QSAR models for predicting the SARS coronavirus main protease inhibition activity of ketone-based covalent inhibitors. <i>Journal of the Iranian Chemical Society</i> , 2022, 19, 1865-1876.	1.2	6
538	Michaelis-like complex of SARS-CoV-2 main protease visualized by room-temperature X-ray crystallography. <i>IUCr</i> , 2021, 8, 973-979.	1.0	25
539	Imaging and visualizing SARS-CoV-2 in a new era for structural biology. <i>Interface Focus</i> , 2021, 11, 20210019.	1.5	5
540	In Silico Identification and Validation of Organic Triazole Based Ligands as Potential Inhibitory Drug Compounds of SARS-CoV-2 Main Protease. <i>Molecules</i> , 2021, 26, 6199.	1.7	9
541	In Silico Target Analysis of Treatment for COVID-19 Using Huang-Lian-Shang-Qing-Wan, a Traditional Chinese Medicine Formula. <i>Natural Product Communications</i> , 2021, 16, 1934578X2110308.	0.2	0
542	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. <i>Current Molecular Medicine</i> , 2022, 22, 621-639.	0.6	2
543	Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome. <i>Cell Reports</i> , 2021, 37, 109892.	2.9	60
544	<scp>Crystalâ€structuresâ€guided</scp> design of <scp>fragmentâ€based</scp> drugs for inhibiting the main protease of <scp>SARSâ€CoV</scp>â€2. <i>Proteins: Structure, Function and Bioinformatics</i> , 2022, 90, 1081-1089.	1.5	5
545	Screening of Potent Phytochemical Inhibitors Against SARS-CoV-2 Main Protease: An Integrative Computational Approach. <i>Frontiers in Bioinformatics</i> , 2021, 1, .	1.0	14
547	Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs. <i>Journal of Molecular Modeling</i> , 2021, 27, 312.	0.8	10
548	Predicting Mutational Effects on Receptor Binding of the Spike Protein of SARS-CoV-2 Variants. <i>Journal of the American Chemical Society</i> , 2021, 143, 17646-17654.	6.6	39
549	Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and <i>In Vitro</i> Study. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5469-5483.	2.5	26
550	DINC-COVID: A webserver for ensemble docking with flexible SARS-CoV-2 proteins. <i>Computers in Biology and Medicine</i> , 2021, 139, 104943.	3.9	8
551	COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. <i>International Journal of Biological Macromolecules</i> , 2021, , .	3.6	14
552	A computational methodology to diagnose sequence-variant dynamic perturbations by comparing atomic protein structures. <i>Bioinformatics</i> , 2021, , .	1.8	0
553	Novel Molecules derived from 3-O-(6-galloyl)glucoside) inhibit Main Protease of SARS-CoV 2 In Silico. <i>Chemical Papers</i> , 2021, , 1-12.	1.0	6
554	Discovery and Nanosized Preparations of (<i>S</i>,<i>R</i>)-Tylophorine Malate as Novel anti-SARS-CoV-2 Agents. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1840-1846.	1.3	8
555	Natural Polyphenols Inhibit the Dimerization of the SARS-CoV-2 Main Protease: The Case of Fortunellin and Its Structural Analogs. <i>Molecules</i> , 2021, 26, 6068.	1.7	11

#	ARTICLE	IF	CITATIONS
559	Investigating an Emerging Virus During a Sudden Pandemic Outbreak. Rambam Maimonides Medical Journal, 2020, 11, e0023.	0.4	0
563	Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease. Journal of Medicinal Chemistry, 2021, 64, 17366-17383.	2.9	32
567	Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein and Cell, 2022, 13, 689-693.	4.8	136
568	Unveiling the Effect of Low pH on the SARS-CoV-2 Main Protease by Molecular Dynamics Simulations. Polymers, 2021, 13, 3823.	2.0	8
569	Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. Journal of Medicinal Chemistry, 2022, 65, 2956-2970.	2.9	46
576	Working goal of Brazilein sappan wood as a candidate for SARS-coV-2 antivirus drug against spike (S) glycoprotein, papain-like proteinase, and main protease: study. Journal of Advanced Pharmaceutical Technology and Research, 2021, 12, 298-304.	0.4	1
577	Current Trends in SPR Biosensing of SARS-CoV-2 Entry Inhibitors. Chemosensors, 2021, 9, 330.	1.8	6
578	Ligand-based quantitative structural assessments of SARS-CoV-2 3CLpro inhibitors: An analysis in light of structure-based multi-molecular modeling evidences. Journal of Molecular Structure, 2022, 1251, 132041.	1.8	12
579	Both Baicalein and Gallocatechin Gallate Effectively Inhibit SARS-CoV-2 Replication by Targeting Mpro and Sepsis in Mice. Inflammation, 2022, 45, 1076-1088.	1.7	23
580	Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease. International Journal of Molecular Sciences, 2021, 22, 12134.	1.8	19
581	Perspectives on SARS-CoV-2 Main Protease Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 16922-16955.	2.9	63
582	Carbon fullerene and nanotube are probable binders to multiple targets of SARS-CoV-2: Insights from computational modeling and molecular dynamic simulation studies. Infection, Genetics and Evolution, 2021, 96, 105155.	1.0	21
583	Current status of therapeutic approaches and vaccines for SARS-CoV-2. Future Microbiology, 2021, 16, 1319-1326.	1.0	2
584	Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources. Microorganisms, 2021, 9, 2481.	1.6	19
585	Dietary polyphenols mitigate SARS-CoV-2 main protease (Mpro)â€™Molecular dynamics, molecular mechanics, and density functional theory investigations. Journal of Molecular Structure, 2022, 1250, 131879.	1.8	16
587	Natural triterpenoids from licorice potently inhibit SARS-CoV-2 infection. Journal of Advanced Research, 2022, 36, 201-210.	4.4	57
588	Heparin interacts with the main protease of SARS-CoV-2 and inhibits its activity. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 267, 120595.	2.0	12
589	Structural and theoretical investigations, Hirshfeld surface analysis and anti-SARS CoV-2 of nickel (II) coordination complex. Journal of Biomolecular Structure and Dynamics, 2023, 41, 402-422.	2.0	9

#	ARTICLE	IF	CITATIONS
590	Design of modular autoproteolytic gene switches responsive to anti-coronavirus drug candidates. <i>Nature Communications</i> , 2021, 12, 6786.	5.8	13
591	Discovery of Diverse Natural Products as Inhibitors of SARS-CoV-2 M ^{pro} Protease through Virtual Screening. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 6094-6106.	2.5	14
592	Novel dynamic residue network analysis approaches to study allosteric modulation: SARS-CoV-2 M ^{pro} and its evolutionary mutations as a case study. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 6431-6455.	1.9	14
593	Computational and In Vitro Experimental Investigations Reveal Anti-Viral Activity of Licorice and Glycyrrhizin against Severe Acute Respiratory Syndrome Coronavirus 2. <i>Pharmaceuticals</i> , 2021, 14, 1216.	1.7	13
594	Inhibition of the SARS-CoV-2 3CL ^{pro} main protease by plant polyphenols. <i>Food Chemistry</i> , 2022, 373, 131594.	4.2	65
595	Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL ^{pro} inhibitors for treating COVID-19. <i>European Journal of Medicinal Chemistry</i> , 2022, 228, 114030.	2.6	19
597	Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity. <i>Journal of the American Chemical Society</i> , 2021, 143, 20697-20709.	6.6	87
598	Automated discovery of noncovalent inhibitors of SARS-CoV-2 main protease by consensus Deep Docking of 40 billion small molecules. <i>Chemical Science</i> , 2021, 12, 15960-15974.	3.7	36
600	Chemical Pattern Recognition for Quality Analysis of <i>Lonicerae Japonicae Flos</i> and <i>Lonicerae Flos</i> Based on Ultra-High Performance Liquid Chromatography and Anti-SARS-CoV2 Main Protease Activity. <i>Frontiers in Pharmacology</i> , 2021, 12, 810748.	1.6	4
601	Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 M ^{pro} protease. <i>PLoS ONE</i> , 2022, 17, e0262482.	1.1	7
602	Screening for Inhibitors of Main Protease in SARS-CoV-2: In Silico and In Vitro Approach Avoiding Peptidyl Secondary Amides. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 350-358.	2.5	15
605	Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases. <i>Biochemical Society Transactions</i> , 2022, 50, 151-165.	1.6	8
606	Discovery of highly potent SARS-CoV-2 M ^{pro} inhibitors based on benzoisothiazolone scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 58, 128526.	1.0	13
607	Efficient discovery of potential inhibitors for SARS-CoV-2 3C-like protease from herbal extracts using a native MS-based affinity-selection method. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 209, 114538.	1.4	18
608	AtualizaÃ§Ãµes dos estudos atuais sobre medicamentos para combater a COVID-19.. <i>Brazilian Journal of Implantology and Health Sciences</i> , 2020, 2, 01-09.	0.0	1
610	Reactivity-guided de novo molecular design and high throughput virtual screening of a targeted library of peptidomimetic compounds reveals charge-based structure-activity relationship of potential covalent inhibitors of the main protease of SARS-CoV-2. <i>Journal of Student Research</i> , 2020, 9,	0.0	0
611	Searching and designing potential inhibitors for SARS-CoV-2 M ^{pro} from natural sources using atomistic and deep-learning calculations. <i>RSC Advances</i> , 2021, 11, 38495-38504.	1.7	11
612	Viral Proteases. , 2021, , 1548-1557.		0

#	ARTICLE	IF	CITATIONS
613	Antiviral activities of natural compounds and ionic liquids to inhibit the Mpro of SARS-CoV-2: a computational approach. RSC Advances, 2022, 12, 3687-3695.	1.7	12
614	Antiviral Effects of Artemisinin and Its Derivatives against SARS-CoV-2 Main Protease: Computational Evidences and Interactions with ACE2 Allelic Variants. Pharmaceuticals, 2022, 15, 129.	1.7	23
615	Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection. SLAS Discovery, 2022, 27, 79-85.	1.4	19
616	Naturally occurring anthraquinones as potential inhibitors of SARS-CoV-2 main protease: an integrated computational study. Biologia (Poland), 2022, 77, 1121-1134.	0.8	5
617	Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Acta Pharmacologica Sinica, 2022, 43, 3021-3033.	2.8	65
618	Unbinding ligands from SARS-CoV-2 Mpro via umbrella sampling simulations. Royal Society Open Science, 2022, 9, 211480.	1.1	9
619	Targeted protein degradation: from small molecules to complex organelles—a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1510, 79-99.	1.8	5
620	Apigenin analogues as SARS-CoV-2 main protease inhibitors: <i>In-silico</i> screening approach. Bioengineered, 2022, 13, 3350-3361.	1.4	18
621	Beyond structural analysis of molecular enzyme-inhibitor interactions. Electronic Structure, 2022, 4, 014006.	1.0	2
622	JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis. MBio, 2022, 13, e0337721.	1.8	14
623	Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 M ^{pro} . RSC Advances, 2022, 12, 3729-3737.	1.7	19
625	A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease. Frontiers in Molecular Biosciences, 2021, 8, 816166.	1.6	8
626	Binding mechanism of inhibitors to SARS-CoV-2 main protease deciphered by multiple replica molecular dynamics simulations. Physical Chemistry Chemical Physics, 2022, 24, 1743-1759.	1.3	25
627	Colorimetric and Electrochemical Methods for the Detection of SARS-CoV-2 Main Protease by Peptide-Triggered Assembly of Gold Nanoparticles. Molecules, 2022, 27, 615.	1.7	22
628	Isatin derivatives as broad-spectrum antiviral agents: the current landscape. Medicinal Chemistry Research, 2022, 31, 244-273.	1.1	28
629	Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary. Molecules, 2022, 27, 850.	1.7	15
630	Pandemic strategies with computational and structural biology against COVID-19: A retrospective. Computational and Structural Biotechnology Journal, 2022, 20, 187-192.	1.9	6
632	Structural insights into the substrate-binding site of main protease for the structure-based COVID-19 drug discovery. Proteins: Structure, Function and Bioinformatics, 2022, 90, 1090-1101.	1.5	5

#	ARTICLE	IF	CITATIONS
633	Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development. <i>Frontiers in Chemistry</i> , 2021, 9, 819165.	1.8	51
634	Biochemical Screening of Potent Zika Virus Protease Inhibitors. <i>ChemMedChem</i> , 2022, 17, e202100695.	1.6	7
635	Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay. <i>ACS Central Science</i> , 2022, 8, 192-204.	5.3	30
636	Structurally diverse glycosides of secoiridoid, bisiridoid, and triterpene-bisiridoid conjugates from the flower buds of two Caprifoliaceae plants and their ATP-citrate lyase inhibitory activities. <i>Bioorganic Chemistry</i> , 2022, 120, 105630.	2.0	4
637	Non-nucleoside structured compounds with antiviral activityâ€”past 10 years (2010â€”2020). <i>European Journal of Medicinal Chemistry</i> , 2022, 231, 114136.	2.6	6
638	In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease. <i>European Journal of Medicinal Chemistry</i> , 2022, 231, 114130.	2.6	16
639	Discovering potent inhibitors against the Mpro of the SARS-CoV-2. A medicinal chemistry approach. <i>Computers in Biology and Medicine</i> , 2022, 143, 105235.	3.9	11
640	Systems pharmacology-based drug discovery and active mechanism of natural products for coronavirus pneumonia (COVID-19): An example using flavonoids. <i>Computers in Biology and Medicine</i> , 2022, 143, 105241.	3.9	15
641	Newly synthesized series of oxindoleâ€”oxadiazole conjugates as potential anti-SARS-CoV-2 agents: <i>in silico</i> and <i>in vitro</i> studies. <i>New Journal of Chemistry</i> , 2022, 46, 5078-5090.	1.4	42
644	Identification of Potential Antiviral Inhibitors from Hydroxychloroquine and 1,2,4,5-Tetraoxanes Analogues and Investigation of the Mechanism of Action in SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1781.	1.8	11
646	Socio-demographic Heterogeneity in Prevalence of SARS-COV-2 Infection and Death Rate: Relevance to Black College Student Knowledge of COVID-19 and SARS-COV-2. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, , 1.	1.8	2
647	SAR and QSAR of COVID-19 Main Proteaseâ€”Inhibitor Interactions of Recently X-ray Crystalized Complexes. <i>Proceedings of the National Academy of Sciences India Section B - Biological Sciences</i> , 2022, 92, 281-291.	0.4	2
648	Case Study of High-Throughput Drug Screening and Remote Data Collection for SARS-CoV-2 Main Protease by Using Serial Femtosecond X-ray Crystallography. <i>Crystals</i> , 2021, 11, 1579.	1.0	9
649	The expression of interleukin-1 β and nuclear factor erythroid-2 in the periodontitis after treatment of liquid smoke rice hull. <i>Journal of Advanced Pharmaceutical Technology and Research</i> , 2022, 13, 95.	0.4	2
650	Mutations in Main Protease of SARS CoV-2 Decreased Boceprevir Affinity. <i>Brazilian Archives of Biology and Technology</i> , 0, 64, .	0.5	1
651	Antiviral cyclic peptides targeting the main protease of SARS-CoV-2. <i>Chemical Science</i> , 2022, 13, 3826-3836.	3.7	29
652	Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide. <i>Chemical Science</i> , 2022, 13, 3027-3034.	3.7	19
653	Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing natureâ€™s toolbox of bioactive compounds. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1306-1344.	1.9	38

#	ARTICLE	IF	CITATIONS
655	Discovery of SARS-CoV-2 3CLPro Peptidomimetic Inhibitors through the Catalytic Dyad Histidine-Specific Proteinâ€“Ligand Interactions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2392.	1.8	3
656	Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review. <i>Frontiers in Pharmacology</i> , 2022, 13, 840639.	1.6	17
657	Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits. <i>Scientific Reports</i> , 2022, 12, 2505.	1.6	41
658	A new inactive conformation of SARS-CoV-2 main protease. <i>Acta Crystallographica Section D: Structural Biology</i> , 2022, 78, 363-378.	1.1	13
660	Fullerenes against COVID-19: Repurposing C60 and C70 to Clog the Active Site of SARS-CoV-2 Protease. <i>Molecules</i> , 2022, 27, 1916.	1.7	11
661	Targeting two potential sites of SARS-CoV-2 main protease through computational drug repurposing. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 3014-3024.	2.0	5
663	SARSâ€“CoVâ€“2 3CL ^{pro} displays faster selfâ€“maturation <i>in vitro</i> than SARSâ€“CoV 3CL ^{pro} due to faster Câ€“terminal cleavage. <i>FEBS Letters</i> , 2022, 596, 1214-1224.	1.3	3
664	Dynamic allostery highlights the evolutionary differences between the CoV-1 and CoV-2 main proteases. <i>Biophysical Journal</i> , 2022, 121, 1483-1492.	0.2	7
666	The naturallyâ€“derived alkaloids as a potential treatment for COVIDâ€“19: A scoping review. <i>Phytotherapy Research</i> , 2022, 36, 2686-2709.	2.8	12
667	From quantumâ€“derived principles underlying cysteine reactivity to combating the COVIDâ€“19 pandemic. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2022, 12, .	6.2	33
669	Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 781039.	1.6	7
670	Systematic Tracing of Susceptible Animals to SARS-CoV-2 by a Bioinformatics Framework. <i>Frontiers in Microbiology</i> , 2022, 13, 781770.	1.5	4
671	Curcumin and Its Analogs as a Therapeutic Strategy in Infections Caused by RNA Genome Viruses. <i>Food and Environmental Virology</i> , 2022, 14, 120-137.	1.5	7
672	In vitro Evaluation of Antiviral Efficacy of a Standardized Hydroalcoholic Extract of Poplar Type Propolis Against SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2022, 13, 799546.	1.5	4
673	Oridonin Inhibits SARSâ€“CoVâ€“2 by Targeting Its 3Câ€“Like Protease. <i>Small Science</i> , 2022, 2, .	5.8	17
674	Performance of COVIDSeq and Swift Normalase Amplicon SARS-CoV-2 Panels for SARS-CoV-2 Genome Sequencing: Practical Guide and Combining FASTQ Strategy. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0002522.	1.8	3
675	Defining A Global Map of Functional Group-based 3D Ligand-binding Motifs. <i>Genomics, Proteomics and Bioinformatics</i> , 2022, 20, 765-779.	3.0	0
676	SARS-CoV-2 nsp5 Exhibits Stronger Catalytic Activity and Interferon Antagonism than Its SARS-CoV Ortholog. <i>Journal of Virology</i> , 2022, 96, e0003722.	1.5	19

#	ARTICLE	IF	CITATIONS
677	In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3987.	1.8	6
678	Electrochemical Biosensor for the Detection of SARS-CoV-2 Main Protease and Its Inhibitor Ebselen. <i>International Journal of Electrochemical Science</i> , 0, , ArticleID:220421.	0.5	1
679	3Î²-Acetoxy-21Î±-H-hop-22(29)ene, a novel multitargeted phytochemical against SARS-CoV-2: in silico screening. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 3884-3891.	2.0	1
680	Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2117142119.	3.3	64
681	Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 834942.	2.2	10
682	Characterization, in-silico, and in-vitro study of a new steroid derivative from <i>Ophiocoma dentata</i> as a potential treatment for COVID-19. <i>Scientific Reports</i> , 2022, 12, 5846.	1.6	6
683	Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. <i>Nature Communications</i> , 2022, 13, 1891.	5.8	45
684	Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332. <i>Journal of Virology</i> , 2022, 96, e0201321.	1.5	34
685	Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 1067-1082.	2.0	23
686	Evaluation of binding performance of bioactive compounds against main protease and mutant model spike receptor binding domain of SARS-CoV-2: Docking, ADMET properties and molecular dynamics simulation study. <i>Journal of the Indian Chemical Society</i> , 2022, 99, 100417.	1.3	8
687	Improved SARS-CoV-2 main protease high-throughput screening assay using a 5-carboxyfluorescein substrate. <i>Journal of Biological Chemistry</i> , 2022, 298, 101739.	1.6	16
688	Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors. <i>Antiviral Research</i> , 2022, 200, 105279.	1.9	2
689	A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors. <i>Antiviral Research</i> , 2022, 201, 105272.	1.9	9
690	Discovery of 4â€²-O-methylscutellarein as a potent SARS-CoV-2 main protease inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2022, 604, 76-82.	1.0	9
691	Multiple protonation states in ligand-free SARS-CoV-2 main protease revealed by large-scale quantum molecular dynamics simulations. <i>Chemical Physics Letters</i> , 2022, 794, 139489.	1.2	5
692	Antiviral activities of 4H-chromen-4-one scaffold-containing flavonoids against SARS-CoV-2 using computational and in vitro approaches. <i>Journal of Molecular Liquids</i> , 2022, 353, 118775.	2.3	15
693	In silico study of potential antiviral activity of copper(II) complexes with non-steroidal anti-inflammatory drugs on various SARS-CoV-2 target proteins. <i>Journal of Inorganic Biochemistry</i> , 2022, 231, 111805.	1.5	7
694	The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19. <i>The Open Covid Journal</i> , 2021, 1, 216-234.	0.4	1

#	ARTICLE	IF	CITATIONS
695	Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery. <i>Frontiers in Pharmacology</i> , 2021, 12, 773198.	1.6	5
696	Impact of Warhead Modulations on the Covalent Inhibition of SARS-CoV-2 M ^{pro} Explored by QM/MM Simulations. <i>ACS Catalysis</i> , 2022, 12, 698-708.	5.5	17
697	Artificial Intelligence in Vaccine and Drug Design. <i>Methods in Molecular Biology</i> , 2022, 2410, 131-146.	0.4	15
700	Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 17846-17865.	2.9	22
701	Impacting Drug Discovery Projects with Large-Scale Enumerations, Machine Learning Strategies, and Free-Energy Predictions. <i>ACS Symposium Series</i> , 0, , 205-226.	0.5	5
702	COVID-19: The question of genetic diversity and therapeutic intervention approaches. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200452.	0.6	1
705	Hydrazones and Thiosemicarbazones Targeting Protein-Protein-Interactions of SARS-CoV-2 Papain-like Protease. <i>Frontiers in Chemistry</i> , 2022, 10, 832431.	1.8	5
706	COVID-19 and retinal degenerative diseases: Promising link â€œKaempferolâ€. <i>Current Opinion in Pharmacology</i> , 2022, 64, 102231.	1.7	11
707	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	6
708	Fast and Effective Prediction of the Absolute Binding Free Energies of Covalent Inhibitors of SARS-CoV-2 Main Protease and 20S Proteasome. <i>Journal of the American Chemical Society</i> , 2022, 144, 7568-7572.	6.6	10
709	Advances in the Development of SARS-CoV-2 M ^{pro} Inhibitors. <i>Molecules</i> , 2022, 27, 2523.	1.7	27
711	Repurposing of Four Drugs as Anti-SARS-CoV-2 Agents and Their Interactions with Protein Targets. <i>Scientia Pharmaceutica</i> , 2022, 90, 24.	0.7	7
712	Pharmaceutical Prospects of Curcuminoids for the Remedy of COVID-19: Truth or Myth. <i>Frontiers in Pharmacology</i> , 2022, 13, 863082.	1.6	8
713	Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E. <i>Virology</i> , 2022, 571, 21-33.	1.1	24
715	A threefold approach including quantum chemical, molecular docking and molecular dynamic studies to explore the natural compounds from <i>Centaurea jacea</i> as the potential inhibitors for COVID-19. <i>Brazilian Journal of Biology</i> , 2021, 83, e247604.	0.4	3
717	Implementation of level-2 biosafety for a macromolecular crystallography beamline at SSRF.. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 529-536.	1.0	0
718	A new insight into the transfer and delivery of anti-SARS-CoV-2 drug Carmofur with the assistance of graphene oxide quantum dot as a highly efficient nanovector toward COVID-19 by molecular dynamics simulation. <i>RSC Advances</i> , 2022, 12, 14167-14174.	1.7	4
719	Metabolomic Profiling of Plasma Reveals Differential Disease Severity Markers in COVID-19 Patients. <i>Frontiers in Microbiology</i> , 2022, 13, 844283.	1.5	15

#	ARTICLE	IF	CITATIONS
721	Synthesis and Applications of Nitrogen-Containing Heterocycles as Antiviral Agents. <i>Molecules</i> , 2022, 27, 2700.	1.7	21
722	A Review of Computational Approaches Targeting SARS-CoV-2 Main Protease to the Discovery of New Potential Antiviral Compounds. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, 3-16.	1.0	3
723	Nanoparticles for Coronavirus Control. <i>Nanomaterials</i> , 2022, 12, 1602.	1.9	9
724	Covalent nirmaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease. <i>Nature Communications</i> , 2022, 13, 2268.	5.8	69
725	An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. <i>Nature Microbiology</i> , 2022, 7, 716-725.	5.9	62
726	Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2022, 30, 139-152.	0.9	9
727	A Review on the Antiviral Activity of Functional Foods Against COVID-19 and Viral Respiratory Tract Infections. <i>International Journal of General Medicine</i> , 2022, Volume 15, 4817-4835.	0.8	5
728	The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114458.	2.6	14
729	Harnessing Natural Products by a Pharmacophore-Oriented Semisynthesis Approach for the Discovery of Potential Anti-SARS-CoV-2 Agents. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	7
730	Harnessing Natural Products by a Pharmacophore-Oriented Semisynthesis Approach for the Discovery of Potential Anti-SARS-CoV-2 Agents. <i>Angewandte Chemie</i> , 0, , .	1.6	0
731	Dimerization Tendency of 3CLpro of Human Coronaviruses Based on the X-ray Crystal Structure of the Catalytic Domain of SARS-CoV-2 3CLpro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5268.	1.8	4
732	The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects. <i>Biophysical Chemistry</i> , 2022, 288, 106824.	1.5	5
733	Crystal structure of SARS-CoV 3C-like protease with baicalein. <i>Biochemical and Biophysical Research Communications</i> , 2022, 611, 190-194.	1.0	10
734	Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0022222.	1.4	39
735	Identification, optimization, and biological evaluation of 3-O- β -chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114426.	2.6	9
736	Benchmarking the ability of novel compounds to inhibit SARS-CoV-2 main protease using steered molecular dynamics simulations. <i>Computers in Biology and Medicine</i> , 2022, 146, 105572.	3.9	28
737	Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease. <i>Biochemical and Biophysical Research Communications</i> , 2022, 616, 8-13.	1.0	5
738	Hijacking of Cellular Functions by Severe Acute Respiratory Syndrome Coronavirus-2. Permeabilization and Polarization of the Host Lipid Membrane by Viroporins. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 4642-4649.	2.1	3

#	ARTICLE	IF	CITATIONS
739	Synthesis and Biochemical Evaluation of 8H-Indeno[1,2-d]thiazole Derivatives as Novel SARS-CoV-2 3CL Protease Inhibitors. <i>Molecules</i> , 2022, 27, 3359.	1.7	1
740	Discovery of C-12 dithiocarbamate andrographolide analogues as inhibitors of SARS-CoV-2 main protease: In vitro and in silico studies. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2784-2797.	1.9	4
742	Integrated computational approach towards repurposing of antimalarial drug against SARS-CoV-2 main protease. <i>Structural Chemistry</i> , 0, , .	1.0	1
743	Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 7818-7832.	2.9	20
744	In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Nucleocapsid Through Molecular Docking-Based Drug Repurposing. <i>Dr Sulaiman Al Habib Medical Journal</i> , 2022, 4, 64-76.	0.3	2
745	Exploration of potential inhibitors for SARS-CoV-2 M ^{pro} considering its mutants via structure-based drug design, molecular docking, MD simulations, MM/PBSA, and DFT calculations. <i>Biotechnology and Applied Biochemistry</i> , 2023, 70, 439-457.	1.4	7
746	Protocetraric and Salazinic Acids as Potential Inhibitors of SARS-CoV-2 3CL Protease: Biochemical, Cytotoxic, and Computational Characterization of Depsidones as Slow-Binding Inactivators. <i>Pharmaceuticals</i> , 2022, 15, 714.	1.7	2
747	Luminescent Assay for the Screening of SARS-CoV-2 M ^{pro} Inhibitors. <i>ChemBioChem</i> , 2022, 23, .	1.3	5
748	VE607 stabilizes SARS-CoV-2 Spike in the RBD-up conformation and inhibits viral entry. <i>IScience</i> , 2022, 25, 104528.	1.9	8
749	Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114508.	2.6	8
750	Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor. <i>Antiviral Research</i> , 2022, 203, 105343.	1.9	12
752	Seeking antiviral drugs to inhibit SARS-CoV-2 RNA dependent RNA polymerase: A molecular docking analysis. <i>PLoS ONE</i> , 2022, 17, e0268909.	1.1	1
755	Maturation of the SARS-CoV-2 virus is regulated by dimerization of its main protease. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3336-3346.	1.9	5
756	Review on development of potential inhibitors of SARS-CoV-2 main protease (M ^{Pro}). <i>Future Journal of Pharmaceutical Sciences</i> , 2022, 8, .	1.1	10
757	Production of a functionally active recombinant SARS-CoV-2 (COVID-19) 3C-like protease and a soluble inactive 3C-like protease-RBD chimeric in a prokaryotic expression system. <i>Epidemiology and Infection</i> , 2022, 150, .	1.0	0
758	Primer for Designing Main Protease (M ^{pro}) Inhibitors of SARS-CoV-2. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 5776-5786.	2.1	8
759	Design of SARS-CoV-2 Main Protease Inhibitors Using Artificial Intelligence and Molecular Dynamic Simulations. <i>Molecules</i> , 2022, 27, 4020.	1.7	14
760	Acrylamide fragment inhibitors that induce unprecedented conformational distortions in enterovirus 71 3C and SARS-CoV-2 main protease. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3924-3933.	5.7	4

#	ARTICLE	IF	CITATIONS
761	Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal. <i>Journal of Computer-Aided Molecular Design</i> , 2022, 36, 483-505.	1.3	4
762	Exploring the potential mechanism of emetine against coronavirus disease 2019 combined with lung adenocarcinoma: bioinformatics and molecular simulation analyses. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
763	Human Superantibodies to 3CLpro Inhibit Replication of SARS-CoV-2 across Variants. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6587.	1.8	3
764	Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 72, 128867.	1.0	5
765	Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8686-8698.	2.9	63
766	Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. <i>Nature Communications</i> , 2022, 13, .	5.8	63
767	Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L. <i>Pharmaceuticals</i> , 2022, 15, 744.	1.7	5
768	De Novo design of potential inhibitors against SARS-CoV-2 Mpro. <i>Computers in Biology and Medicine</i> , 2022, 147, 105728.	3.9	6
769	Bioactive prenylated phenolic compounds from the aerial parts of <i>Glycyrrhiza uralensis</i> . <i>Phytochemistry</i> , 2022, 201, 113284.	1.4	6
770	Genomic, proteomic and metabolomic profiling of severe acute respiratory syndrome-Coronavirus-2. , 2022, , 49-76.		0
771	Databases, DrugBank, and virtual screening platforms for therapeutic development. , 2022, , 291-334.		0
772	Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2. , 2022, , 451-488.		0
773	BRET-Based Self-Cleaving Biosensors for SARS-CoV-2 3CLpro Inhibitor Discovery. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5
774	Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening. <i>PLoS ONE</i> , 2022, 17, e0269563.	1.1	9
775	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
776	Viofree, an Herbal Medicine-Based Formula, Interrupts the Viral Infection of Delta and Omicron Variants of SARS-CoV-2. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
777	Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort. <i>Scientific Data</i> , 2022, 9, .	2.4	17
779	The Main Protease of SARS-CoV-2 as a Target for Phytochemicals against Coronavirus. <i>Plants</i> , 2022, 11, 1862.	1.6	13

#	ARTICLE	IF	CITATIONS
780	How Reproducible Are QM/MM Simulations? Lessons from Computational Studies of the Covalent Inhibition of the SARS-CoV-2 Main Protease by Carmofur. <i>Journal of Chemical Theory and Computation</i> , 2022, 18, 5056-5067.	2.3	9
781	Self-Masked Aldehyde Inhibitors of Human Cathepsin L Are Potent Anti-CoV-2 Agents. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	5
782	The SARS-CoV-2 main protease (M ^{pro}): Structure, function, and emerging therapies for COVID-19. <i>MedComm</i> , 2022, 3, .	3.1	79
783	From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease. <i>Molecules</i> , 2022, 27, 4292.	1.7	10
784	Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease. <i>Scientific Reports</i> , 2022, 12, .	1.6	20
785	Fragment-based inhibitor design for SARS-CoV2 main protease. <i>Structural Chemistry</i> , 2022, 33, 1467-1487.	1.0	1
786	Vibrational spectroscopic signatures, effect of rehybridization and hyperconjugation on the dimer molecule of N ⁴ -(4-chlorophenyl)-2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]acetamide- quantum 0.5 computational approach. <i>Spectroscopy Letters</i> , 0, , 1-17.	0.5	2
787	Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CL ^{pro}) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 5915-5945.	2.0	7
788	Molecular docking and machine learning affinity prediction of compounds identified upon softwood bark extraction to the main protease of the SARS-CoV-2 virus. <i>Biophysical Chemistry</i> , 2022, 288, 106854.	1.5	6
789	A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114596.	2.6	24
790	A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114570.	2.6	23
791	Oral antiviral treatments for COVID-19: opportunities and challenges. <i>Pharmacological Reports</i> , 2022, 74, 1255-1278.	1.5	31
792	Proteome-Wide Profiling of the Covalent-Druggable Cysteines with a Structure-Based Deep Graph Learning Network. <i>Research</i> , 2022, 2022, .	2.8	4
793	Solanaceae Family Phytochemicals as Inhibitors of 3C-Like Protease of SARS-CoV-2: An In Silico Analysis. <i>Molecules</i> , 2022, 27, 4739.	1.7	2
794	A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 1345-1350.	1.3	23
795	A ricin-based peptide BRIP from <i>Hordeum vulgare</i> inhibits M ^{pro} of SARS-CoV-2. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
796	Theaflavin 3-gallate inhibits the main protease (M ^{pro}) of SARS-CoV-2 and reduces its count in vitro. <i>Scientific Reports</i> , 2022, 12, .	1.6	17
797	Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. <i>Journal of Clinical Medicine</i> , 2022, 11, 4464.	1.0	13

#	ARTICLE	IF	CITATIONS
798	Ligand-based design, synthesis, computational insights, and <i>in vitro</i> studies of novel <i>N</i> -(5-Nitrothiazol-2-yl)-carboxamido derivatives as potent inhibitors of SARS-CoV-2 main protease. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 2112-2132.	2.5	21
799	Targeting SARS-CoV-2 papain-like protease in the postvaccine era. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 906-919.	4.0	22
800	Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M ^{pro} and Papain-like Protease PL ^{pro} of SARS-CoV-2. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 6553-6573.	2.5	19
801	COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2211-2233.	0.9	1
802	Evaluation of the anti-SARS-CoV-2 properties of essential oils and aromatic extracts. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
804	Structure-based design of anti-mycobacterial drug leads that target the mycolic acid transporter MmpL3. <i>Structure</i> , 2022, , .	1.6	2
805	Schaftoside inhibits 3CL ^{pro} and PL ^{pro} of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 4154-4164.	5.7	28
806	Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites. <i>Cell Host and Microbe</i> , 2022, 30, 1354-1362.e6.	5.1	28
807	In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	15
808	Repurposing small molecules of <i>Tephrosia purpurea</i> against SARS-CoV-2 main protease. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 6822-6833.	2.0	0
809	Identification of a Dual Inhibitor of Secreted Phospholipase A2 (GIIA sPLA2) and SARS-CoV-2 Main Protease. <i>Pharmaceuticals</i> , 2022, 15, 961.	1.7	3
810	Plant-derived compounds effectively inhibit the main protease of SARS-CoV-2: An in silico approach. <i>PLoS ONE</i> , 2022, 17, e0273341.	1.1	7
811	Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	16
812	Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an <i>in silico</i> study. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 23391-23401.	1.3	2
813	Deciphering the binding mechanism of inhibitors of the SARS-CoV-2 main protease through multiple replica accelerated molecular dynamics simulations and free energy landscapes. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 22129-22143.	1.3	16
814	Traditional Chinese Medicine JingYinGuBiao Formula Therapy Improves the Negative Conversion Rate of SARS-CoV2 in Patients with Mild COVID-19. <i>International Journal of Biological Sciences</i> , 2022, 18, 5641-5652.	2.6	9
815	Searching for potential inhibitors of SARS-COV-2 main protease using supervised learning and perturbation calculations. <i>Chemical Physics</i> , 2023, 564, 111709.	0.9	6
816	Targeting the SARS-CoV-2 Spike Protein with the Usage of an Internet of Viral and Bacterial Things. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
817	Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival. <i>Viruses</i> , 2022, 14, 1893.	1.5	3
818	Redox stress in COVID-19: Implications for hematologic disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101373.	0.7	0
820	Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10716.	1.8	5
821	A reporter cell line for the automated quantification of SARS-CoV-2 infection in living cells. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
822	A computational study of metal-organic frameworks (MOFs) as potential nanostructures to combat SARS-CoV-2. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
823	Label-free Sensing of Main Protease Activity of SARS-CoV-2 with an Aerolysin Nanopore. <i>Chemistry - an Asian Journal</i> , 2022, 17, .	1.7	4
824	High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors. <i>Protein and Cell</i> , 0, , .	4.8	2
825	A computational insight on the inhibitory potential of 8-Hydroxydihydrosanguinarine (8-HDS), a pyridone containing analogue of sanguinarine, against SARS CoV2.. <i>Chemistry and Biodiversity</i> , 0, , .	1.0	6
826	Antiviral activity of <i>Cenostigma pluviosum</i> var. <i>peltophoroides</i> extract and fractions against SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 7297-7308.	2.0	5
827	Target-Specific Machine Learning Scoring Function Improved Structure-Based Virtual Screening Performance for SARS-CoV-2 Drugs Development. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11003.	1.8	11
828	Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	23
829	Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 13328-13342.	2.9	13
830	The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS-CoV-2 and Cytokine Storm. <i>Chemistry and Biodiversity</i> , 2022, 19, .	1.0	10
831	Computational Evidence Based Perspective on the Plausible Repositioning of Fluoroquinolones for COVID-19 Treatment. <i>Current Computer-Aided Drug Design</i> , 2022, 18, 407-413.	0.8	2
832	A genetically encoded BRET-based SARS-CoV-2 Mpro protease activity sensor. <i>Communications Chemistry</i> , 2022, 5, .	2.0	9
833	Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 12500-12534.	2.9	49
834	Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-70.	0.7	13
835	The Natural Products Withaferin A and Withanone from the Medicinal Herb <i>Withania somnifera</i> Are Covalent Inhibitors of the SARS-CoV-2 Main Protease. <i>Journal of Natural Products</i> , 2022, 85, 2340-2350.	1.5	11

#	ARTICLE	IF	CITATIONS
836	Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 13343-13364.	2.9	36
837	Screening Active Phytochemicals of Some Ayurvedic Medicinal Plants to Identify Potential Inhibitors against SARS-CoV-2 Mpro by Computational Investigation. <i>Letters in Drug Design and Discovery</i> , 2023, 20, 1380-1392.	0.4	0
838	Druggable targets and therapeutic development for COVID-19. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	4
839	Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro. <i>Antiviral Research</i> , 2022, 207, 105419.	1.9	7
840	Multi-targeted molecular docking, pharmacokinetics, and drug-likeness evaluation of coumarin based compounds targeting proteins involved in development of COVID-19. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 103458.	1.8	4
841	Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen. <i>European Journal of Medicinal Chemistry</i> , 2022, 244, 114803.	2.6	12
842	Agathisflavone, a natural biflavonoid that inhibits SARS-CoV-2 replication by targeting its proteases. <i>International Journal of Biological Macromolecules</i> , 2022, 222, 1015-1026.	3.6	16
843	Molecular-Level Targets for the Development of Therapies Against Coronavirus Diseases. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 69-84.	0.1	0
844	Candidate Drugs for the Potential Treatment of Coronavirus Diseases. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 85-114.	0.1	0
845	Recent computational drug repositioning strategies against SARS-CoV-2. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5713-5728.	1.9	3
846	Advances in research on 3C-like protease (3CL ^{pro}) inhibitors against SARS-CoV-2 since 2020. <i>RSC Medicinal Chemistry</i> , 2023, 14, 9-21.	1.7	15
847	Advanced approaches of developing targeted covalent drugs. <i>RSC Medicinal Chemistry</i> , 2022, 13, 1460-1475.	1.7	7
848	Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. <i>Molecular Aspects of Medicine</i> , 2023, 91, 101151.	2.7	16
849	In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. <i>Antiviral Research</i> , 2022, 208, 105450.	1.9	13
850	A Review of Potential Therapeutic Strategies for COVID-19. <i>Viruses</i> , 2022, 14, 2346.	1.5	3
851	Identification of Cysteine 270 as a Novel Site for Allosteric Modulators of SARS-CoV-2 Papain-Like Protease**. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	9
852	Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
853	Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	7

#	ARTICLE	IF	CITATIONS
854	Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 13852-13865.	2.9	17
855	Anticoagulants as Potential SARS-CoV-2 Mpro Inhibitors for COVID-19 Patients: In Vitro, Molecular Docking, Molecular Dynamics, DFT, and SAR Studies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12235.	1.8	18
856	Dual-Reporter System for Real-Time Monitoring of SARS-CoV-2 Main Protease Activity in Live Cells Enables Identification of an Allosteric Inhibition Path. <i>ACS Bio & Med Chem Au</i> , 2022, 2, 627-641.	1.7	1
857	Identification of Cysteine 270 as a Novel Site for Allosteric Modulators of SARS-CoV-2 Papain-Like Protease. <i>Angewandte Chemie</i> , 0, , .	1.6	0
858	Qualitative Estimation of Protein-Ligand Complex Stability through Thermal Titration Molecular Dynamics Simulations. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 5715-5728.	2.5	17
859	Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
860	Easy access to Î±-ketoamides as SARS-CoV-2 and MERS Mpro inhibitors via the PADAM oxidation route. <i>European Journal of Medicinal Chemistry</i> , 2022, 244, 114853.	2.6	8
861	Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2. <i>European Journal of Medicinal Chemistry</i> , 2022, 244, 114857.	2.6	7
862	Quinone and SARS-CoV-2. , 2023, , 47-81.		0
863	The Artistic and Scientific Nature of Protein Structure: A Historical Overview. <i>Integrated Science</i> , 2022, , 625-648.	0.1	0
864	Characterizing the ligand-binding affinity toward SARS-CoV-2 Mpro via physics- and knowledge-based approaches. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 29266-29278.	1.3	4
865	Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses. <i>Bioorganic Chemistry</i> , 2023, 130, 106264.	2.0	5
866	Efficacy Evaluation of Quercetin and Its Analogues on the Main Protease Enzyme of the COVID-19 Using Molecular Docking Studies. <i>Majallah-i Dānishgāh-i Ārshād-i Pizishk-i Ālām</i> , 2022, 30, 66-85.	0.1	0
867	Dual Inhibitors of Main Protease (M ^{Pro}) and Cathepsin L as Potent Antivirals against SARS-CoV2. <i>Journal of the American Chemical Society</i> , 2022, 144, 21035-21045.	6.6	20
869	Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development. <i>Molecules</i> , 2022, 27, 7728.	1.7	18
870	Proteolysis and Deficiency of Î±1-Proteinase Inhibitor in SARS-CoV-2 Infection. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2022, 16, 271-291.	0.2	1
871	Novel CYP11A1-Derived Vitamin D and Lumisterol Biometabolites for the Management of COVID-19. <i>Nutrients</i> , 2022, 14, 4779.	1.7	14
872	The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	2

#	ARTICLE	IF	CITATIONS
873	The exploration of phytochemicals theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion. <i>Journal of Infection and Public Health</i> , 2023, 16, 42-54.	1.9	4
874	<i>In silico</i> molecular docking, dynamics simulation and repurposing of some VEGFR-2 inhibitors based on the SARS-CoV-2-main-protease inhibitor N3. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 9267-9281.	2.0	4
875	Green and Regioselective Approach for the Synthesis of 3-Substituted Indole Based 1,2-Dihydropyridine and Azaxanthone Derivatives as a Potential Lead for SARS-CoV-2 and Delta Plus Mutant Virus: DFT and Docking Studies. <i>ACS Omega</i> , 0, , .	1.6	3
876	Computational investigation of natural compounds as potential main protease (Mpro) inhibitors for SARS-CoV-2 virus. <i>Computers in Biology and Medicine</i> , 2022, 151, 106318.	3.9	12
877	Optimization of potential non-covalent inhibitors for the SARS-CoV-2 main protease inspected by a descriptor of the subpocket occupancy. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 29940-29951.	1.3	3
878	TEMPO: A transformer-based mutation prediction framework for SARS-CoV-2 evolution. <i>Computers in Biology and Medicine</i> , 2023, 152, 106264.	3.9	4
879	Electronic structures of zwitterionic and protonated forms of glycine betaine in water: Insights into solvent effects from ab initio simulations. <i>Journal of Molecular Liquids</i> , 2023, 369, 120871.	2.3	5
880	Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2023, 247, 115021.	2.6	11
881	Discovery and structural optimization of 3-O- β -Chacotriosyl betulonic acid saponins as potent fusion inhibitors of Omicron virus infections. <i>Bioorganic Chemistry</i> , 2023, 131, 106316.	2.0	4
882	Analysis and Identification of Bioactive Compounds of Cannabinoids in Silico for Inhibition of SARS-CoV-2 and SARS-CoV. <i>Biomolecules</i> , 2022, 12, 1729.	1.8	2
883	Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets. <i>Pharmaceuticals</i> , 2022, 15, 1478.	1.7	1
884	Understanding Cysteine Chemistry Using Conventional and Serial X-ray Protein Crystallography. <i>Crystals</i> , 2022, 12, 1671.	1.0	1
885	QSAR of SARS-CoV-2 Main Protease Inhibitors Utilizing Theoretical Molecular Descriptors. <i>Letters in Drug Design and Discovery</i> , 2022, 20, .	0.4	2
886	Small molecules in the treatment of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	42
887	Pharmacophore-Based Virtual Screening of Potential SARS-CoV-2 Main Protease Inhibitors from Library of Natural Products. <i>Natural Product Communications</i> , 2022, 17, 1934578X2211436.	0.2	3
888	Characterization and protein engineering of glycosyltransferases for the biosynthesis of diverse hepatoprotective cycloartane-type saponins in <i>Astragalus membranaceus</i> . <i>Plant Biotechnology Journal</i> , 2023, 21, 698-710.	4.1	5
889	Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 16902-16917.	2.9	15
891	Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site. <i>PLoS Pathogens</i> , 2022, 18, e1011065.	2.1	10

#	ARTICLE	IF	CITATIONS
892	Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CLpro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 16011.	1.8	2
893	Potential inhibitory properties of structurally modified quercetin/isohamnetin glucosides against SARS-CoV-2 Mpro; molecular docking and dynamics simulation strategies. <i>Informatics in Medicine Unlocked</i> , 2023, 37, 101167.	1.9	1
894	Flavonoids from the roots and rhizomes of <i>Sophora tonkinensis</i> and their in vitro anti-SARS-CoV-2 activity. <i>Chinese Journal of Natural Medicines</i> , 2023, 21, 65-80.	0.7	1
895	Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells. <i>Chemical Science</i> , 2023, 14, 1666-1672.	3.7	1
896	Structural Analysis and Epitope Prediction of S2 Domain of SARS-CoV-2, Conservation Analysis Among Major Variants. <i>Viral Immunology</i> , 0, , .	0.6	0
897	Drug repurposing screening validated by experimental assays identifies two clinical drugs targeting SARS-CoV-2 main protease. <i>Frontiers in Drug Discovery</i> , 0, 2, .	1.1	1
898	A knowledge-based protein-protein interaction inhibition (KPI) pipeline: an insight from drug repositioning for COVID-19 inhibition. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-14.	2.0	0
899	Multi-ligand molecular docking, simulation, free energy calculations and wavelet analysis of the synergistic effects between natural compounds baicalein and cubebin for the inhibition of the main protease of SARS-CoV-2. <i>Journal of Molecular Liquids</i> , 2023, 374, 121253.	2.3	7
900	A Novel Y-Shaped, Sâ€™Oâ€™Nâ€™S-Bridged Cross-Link between Three Residues C22, C44, and K61 Is Frequently Observed in the SARS-CoV-2 Main Protease. <i>ACS Chemical Biology</i> , 2023, 18, 449-455.	1.6	5
901	Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics. <i>International Journal of Antimicrobial Agents</i> , 2023, 61, 106708.	1.1	13
902	â€™Poly phenolic phytoceutical loaded nano-bilosomes for enhanced caco-2 cell permeability and SARS-CoV 2 antiviral activityâ€™™: in-vitro and insilico studies. <i>Drug Delivery</i> , 2023, 30, .	2.5	9
903	Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2. <i>Nature Microbiology</i> , 2023, 8, 121-134.	5.9	6
904	Interactions of SARS-CoV-2 and MERS-CoV fusion peptides measured using single-molecule force methods. <i>Biophysical Journal</i> , 2023, 122, 646-660.	0.2	1
905	SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies. <i>Future Pharmacology</i> , 2023, 3, 80-107.	0.6	9
906	Computational Repurposing of Potential Dimerization Inhibitors against SARS-CoV-2 Main Protease. <i>Letters in Drug Design and Discovery</i> , 2024, 21, 799-808.	0.4	0
907	A comprehensive perspective of traditional Arabic or Islamic medicinal plants as an adjuvant therapy against COVID-19. <i>Saudi Journal of Biological Sciences</i> , 2023, 30, 103561.	1.8	1
908	In silico Screening of Potential SARS-CoV-2 Main Protease Inhibitors from <i>Thymus schimperii</i> . <i>Advances and Applications in Bioinformatics and Chemistry</i> , 0, Volume 16, 1-13.	1.6	0
909	Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design. <i>Chemico-Biological Interactions</i> , 2023, 371, 110352.	1.7	3

#	ARTICLE	IF	CITATIONS
910	Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 181-194.	2.5	6
911	Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro. <i>ACS Central Science</i> , 2023, 9, 217-227.	5.3	23
912	Recent updates on the biological efficacy of approved drugs and potent synthetic compounds against SARS-CoV-2. <i>RSC Advances</i> , 2023, 13, 3677-3687.	1.7	4
913	Potential of plant extracts in targeting SARS-CoV-2 main protease: an <i>in vitro</i> and <i>in silico</i> study. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-10.	2.0	3
914	Oxazolidinones Antibiotics, Chemistry, Applications and Role in COVID-19 Treatment. <i>Pharmacology & Pharmacy</i> , 2023, 14, 19-32.	0.2	1
915	Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection. <i>Cell Reports Physical Science</i> , 2023, , 101249.	2.8	1
916	Synthesis and enzymatic inhibition effects of thiazolidinedione 3C-like protease inhibitors. <i>Journal of Chemical Research</i> , 2023, 47, 174751982311525.	0.6	0
917	Oriented Immobilization of G Protein-Coupled Receptors. <i>Springer Briefs in Molecular Science</i> , 2023, , 41-63.	0.1	0
918	Thermal Titration Molecular Dynamics (TTMD): Not Your Usual Post-Docking Refinement. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3596.	1.8	8
919	In silico screening of phenylethanoid glycosides, a class of pharmacologically active compounds as natural inhibitors of SARS-CoV-2 proteases. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 1461-1472.	1.9	3
920	Quantitative analysis of high-throughput biological data. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2023, 13, .	6.2	2
921	Artificial intelligence based virtual screening study for competitive and allosteric inhibitors of the SARS-CoV-2 main protease. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 15286-15304.	2.0	3
922	Evolutionary aspects of mutation in functional motif and post-translational modifications in SARS-CoV-2 3CLpro (Mpro): an in-silico study. <i>Journal of Proteins and Proteomics</i> , 2023, 14, 99-109.	1.0	3
924	Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332. <i>Biochemical and Biophysical Research Communications</i> , 2023, 657, 16-23.	1.0	0
925	Octyl gallate targeting the 3C-like protease exhibits highly efficient antiviral activity against swine enteric coronavirus PEDV. <i>Veterinary Microbiology</i> , 2023, 281, 109743.	0.8	3
926	Molecular insights into the inhibition mechanism of harringtonine against essential proteins associated with SARS-CoV-2 entry. <i>International Journal of Biological Macromolecules</i> , 2023, 240, 124352.	3.6	3
927	COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. <i>Drug Discovery Today</i> , 2023, 28, 103579.	3.2	22
928	Synthesis, molecular docking, and binding Gibbs free energy calculation of β -nitrostyrene derivatives: Potential inhibitors of SARS-CoV-2 3CL protease. <i>Journal of Molecular Structure</i> , 2023, 1284, 135409.	1.8	4

#	ARTICLE	IF	CITATIONS
929	Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114367.	2.5	33
930	Recent Advances in N-Heterocycles for COVID-19 Treatment - A Mini Review. <i>Medicinal Chemistry</i> , 2023, 19, 717-729.	0.7	0
931	A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	20
932	Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV). <i>European Journal of Medicinal Chemistry</i> , 2023, 254, 115376.	2.6	7
933	Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2. <i>European Journal of Medicinal Chemistry</i> , 2023, 249, 115129.	2.6	6
934	Comparative Analysis of Library Preparation Approaches for SARS-CoV-2 Genome Sequencing on the Illumina MiSeq Platform. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2374.	1.8	0
935	Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19. <i>Pharmaceuticals</i> , 2023, 16, 190.	1.7	10
936	Targeting viral proteins for restraining SARS-CoV-2: focusing lens on viral proteins beyond spike for discovering new drug targets. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 247-268.	2.5	1
937	Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches. <i>Molecular Biotechnology</i> , 0, , .	1.3	6
938	Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses. <i>Antiviral Research</i> , 2023, 211, 105555.	1.9	11
939	The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms. <i>Chemical Science</i> , 2023, 14, 2686-2697.	3.7	6
940	Virtual screening of bioactive anti-SARS-CoV natural products and identification of 3Î²,12-diacetoxyabieta-6,8,11,13-tetraene as a potential inhibitor of SARS-CoV-2 virus and its infection related pathways by MD simulation and network pharmacology. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 13923-13936.	2.0	1
941	AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 1438-1453.	2.5	4
942	Machine learning combines atomistic simulations to predict SARS-CoV-2 Mpro inhibitors from natural compounds. <i>Molecular Diversity</i> , 0, , .	2.1	1
943	Sulforaphane is a reversible covalent inhibitor of 3Î±chymotrypsinÎ±like protease of SARS-CoV-2. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4
944	Anti-Coronaviral Nanocluster Restrains Infections of SARS-CoV-2 and Associated Mutants through Virucidal Inhibition and 3CL Protease Inactivation. <i>Advanced Science</i> , 2023, 10, .	5.6	4
946	Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 3664-3702.	2.9	12
947	COVID-19 and Cancer Diseases-The Potential of Coriolus versicolor Mushroom to Combat Global Health Challenges. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4864.	1.8	4

#	ARTICLE	IF	CITATIONS
949	Designing Potential Inhibitors of SARS-CoV-2 Mpro Using Deep Learning and Steered Molecular Dynamic Simulations. <i>Journal of Computational Biophysics and Chemistry</i> , 2023, 22, 525-540.	1.0	0
950	Biophysical Interpretation of Evolutionary Consequences on the SARS-CoV2 Main Protease through Molecular Dynamics Simulations and Network Topology Analysis. <i>Journal of Physical Chemistry B</i> , 2023, 127, 2331-2343.	1.2	1
952	Development of the Safe and Broad-Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained Î±, Î³-AA Peptide Scaffold. <i>Chemistry - A European Journal</i> , 2023, 29, .	1.7	3
953	Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2023, 86, 129238.	1.0	3
955	In silico and in vitro evaluation of antiviral activity of wogonin against main protease of porcine epidemic diarrhea virus. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	0
956	Insights into targeting SARS-CoV-2: design, synthesis, <i>in silico</i> studies and antiviral evaluation of new dimethylxanthine derivatives. <i>RSC Medicinal Chemistry</i> , 2023, 14, 899-920.	1.7	1
957	Exploiting the co-crystal ligands shape, features and structure-based approaches for identification of SARS-CoV-2 Mpro inhibitors. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-14.	2.0	2
958	Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 15262-15285.	2.0	1
959	How SARS-CoV-2 Alters the Regulation of Gene Expression in Infected Cells. <i>Journal of Physical Chemistry Letters</i> , 2023, 14, 3199-3207.	2.1	2
960	Discovery of Potential Inhibitors of SARS-CoV-2 Main Protease by a Transfer Learning Method. <i>Viruses</i> , 2023, 15, 891.	1.5	3
961	Virtual and In Vitro Screening of Natural Products Identifies Indole and Benzene Derivatives as Inhibitors of SARS-CoV-2 Main Protease (Mpro). <i>Biology</i> , 2023, 12, 519.	1.3	4
962	SARS-CoV-2 polyprotein substrate regulates the stepwise Mpro cleavage reaction. <i>Journal of Biological Chemistry</i> , 2023, 299, 104697.	1.6	2
963	Binding kinetics study of SARS-CoV-2 main protease and potential inhibitors <i>via</i> molecular dynamics simulations. <i>Physical Chemistry Chemical Physics</i> , 0, , .	1.3	1
964	Exploring potential SARS-CoV-2 Mpro non-covalent inhibitors through docking, pharmacophore profile matching, molecular dynamic simulation, and MM-GBSA. <i>Journal of Molecular Modeling</i> , 2023, 29, .	0.8	0
966	Antiviral and Possible Prophylactic Significance of Myricetin for COVID-19. <i>Natural Product Communications</i> , 2023, 18, 1934578X2311662.	0.2	2
984	¹ Glutamine isosteres in the design of inhibitors of 3C/3CL protease of human viruses of the <i>Pisoniviricetes</i> class. <i>RSC Chemical Biology</i> , 2023, 4, 533-547.	2.0	2
993	Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3
1019	Rapid resistance profiling of SARS-CoV-2 protease inhibitors. , 2023, 1, .		6

#	ARTICLE	IF	CITATIONS
1049	Traditional Herbal Medicines and Their Active Constituents in Combating SARS-CoV-2 Infection. , 2023, , 137-188.		0
1083	Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2. RSC Advances, 2023, 13, 35500-35524.	1.7	0
1089	Quantum Chemistry in Drug Design: Density Function Theory (DFT) and Other Quantum Mechanics (QM)-related Approaches. , 2023, , 258-309.		0
1091	SARS-CoV-2 Spike Protein: A Review of Structure, Function, Care, Vaccines, and Possible Inhibitors Designed by Molecular Modeling. Engineering Materials, 2024, , 271-289.	0.3	0
1095	Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19. Frontiers of Medicine, 2023, 17, 1014-1029.	1.5	0
1102	Structure-Based Screening of Potential Drugs against SARS-CoV-2 Variants. , 0, , .		0